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This study was conducted to establish the scientific basis of the reported ethnomedicinal use of 
Ihlamvu laseAfrika (IHL) against Human Immunodeficiency Virus (HIV) and Acquired 
Immunodeficiency Virus (AIDS) related infections. IHL is believed to have a positive effect on 
AIDS however this has neither been clinically nor laboratory proven. Such effect can either be 
directly due to IHL’s inhibition of the virus causing AIDS or indirectly by the inhibition of 
organisms causing opportunistic infections. Experiments were carried out to test for the effect of 
IHL against Cryptococcus neoformans, Candida albicans, Herpes Simplex Virus (HSV), 
Mycobacterium tuberculosis (MTB) and HIV. 
The toxicity of IHL was determined by means of three assays. Using the Trypan Blue 
Dye exclusion test, an aqueous mixture of IHL was tested on Vero cells (African Green Monkey) 
for acute toxicity at two concentrations. Cell membranes compromised by IHL would take up dye 
and eventually spill their contents. Vero cells that were exposed to 1µg/mL and 100µg/mL 
concentrations of IHL for 7 hours resulted in (8.9±0.15) % and (98.7±0.84) % cell viability (n=3), 
respectively. When the duration of incubation increased to 48 hours, percentage cell viability of 
1µg/mL and 100µg/mL concentrations were (98.3±0.50) and (98.2±0.50) respectively. 
 The second cytotoxicity test involved incorporation an aqueous mixture of IHL onto 3-
(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT). Cells were incubated in 
IHL for 24 and 48 hours resulting in a decrease in cell viability in a dose-dependent manner. At 
the lowest IHL concentration (0.1µg/mL) the cell viability was 80% and 78.5% after 24 and 48 
hours incubations, respectively whereas at the highest concentration (1000µg/mL) was used in 24 
and 48 hours incubation, cell viability was 50% and 80% respectively. 
 The third cytotoxicity test called glutathione (GSH) focused on antioxidant level. The 




were 0.23; 0.46; 0.94; 1.88; 3.75; 7.50; 15.0 and 30.0 mg/mL. The results showed that the 
antioxidants levels were reduced in proportions relative to IHL concentration levels. The safe and 
effective dose of IHL obtained was 1.88mg/mL. 
 The second objective of the study was to determine IHL’s active principle that is capable 
of inhibiting growth of C. albicans and C. neoformans, HSV, MTB and HIV. Solvents such as 
methanol, ethanol and acetone were utilized including an aqueous extract to extract it. The most 
suitable extract to inhibit the proliferation of the aforementioned organisms needed to be 
established. Upon its establishment, it was then used to determine the minimum inhibitory 
concentration (MIC). This was done in all susceptibility tests except for HIV whereby a ‘neat 
substance’ was used. In the case of HSV a causative agent for herpes, its susceptibility towards 
several IHL extracts was assessed with real-time polymerase chain reaction (RT-PCR). PCR 
attenuates specific site of DNA and quantifies viral load and the focus was the UL30 position 
which is targeted by most drugs. When comparing all solvent extracts as well as an aqueous 
extract of similar concentration, it was found that the methanol extract emerged as the strongest 
viral inhibitor with the lowest viral yield, and its threshold value, Ct = 18.4± 0.86 while the IHL 
concentration was 1.88mg/mL. The MIC of the methanol extract was 1.25mg/mL and 
Ct=18.9±1.14. An acetone extract proved to be the weakest thus its viral load was the highest, its 
Ct= (8.50±1.33) whilst IHL concentration was 1.88mg/mL.   
Cryptococcus neoformans known for causing meningitis and encephalitis in AIDS 
patients and C. albicans a causative agent for vaginal and oral thrush were two opportunistic 
infections tested for susceptibility towards IHL. The disk diffusion method was used for both 
fungal organisms. The best suited solvent extract was established and then used to determine the 
MIC. An aqueous extract showed the best activity with the inhibition zones of (10.5±1.642) mm 




extract (8.80 ±1.21) mm had the lowest activity. The MIC of IHL’s aqueous extract was 
1.0mg/mL and the corresponding zone of inhibition was (10.6±1.34) mm. 
When C. neoformans was tested for susceptibility against various IHL solvent extracts, 
the IHL’s aqueous extract had inhibition zones of (21.1±2.40) mm thus emerged as the strongest 
followed by methanol extract (10.3±0.43) mm while ethyl acetate extract was least active 
(7.13±0.33) mm. The MIC of the aqueous extract was 1.0mg/mL and its corresponding zone of 
inhibition was (11.4±0.55) mm. Furthermore, the growth inhibition of both C. neoformans and C. 
albicans by IHL’s aqueous extract were confirmed in liquid media with broth microdilution 
method. This technique tends to mimic what is likely to happen in a biological fluid. The results 
obtained depicted a dose-dependent response and both organisms shared a common MIC of 
2.0mg/mL. From the broth microtitre plate aliquots samples were plated onto agar and used to 
further determine the minimum lethal concentration (MLC). The MLC essentially determines the 
antifungal concentration of an agent at which no colonies displayed visible growth. The MLC’s 
of IHL towards C. albicans and C. neoformans were 32 and 8 mg/mL respectively. IHL proved 
fungicidal at higher concentrations and fungistatic at low concentrations. 
Further susceptibility tests of IHL extracts were carried out on bacterial pathogens such 
as the MTB, a causative agent for Tuberculosis with 1% proportion method. This method seeks to 
determine if isolates are resistant if colonies grown in the presence of drugs are greater or equal to 
1% of colonies grown in drug-free control quadrant. The best solvent extract was determined and 
then used to determine the MIC. Acetone extract results were 0.2% meaning that it strongly 
inhibited growth of MTB better than ethyl acetate (5%) and others the worst results were that of 
an aqueous extract (113%). A confirmation exercise was done with an agar dilution method. All 
extracts were incorporated onto agar and MTB colonies growing relative to negative controls after 
21 days of incubation meant resistance while no growth meant susceptible. The MTB strain again 




aqueous extracts. The dichloromethane and ethyl acetate extracts seemed to have damaged the 
polypropylene plates rendering results null and void. Using agar dilution method, an MIC of an 
acetone extract was 16mg/mL. 
An aqueous extract was used for assessing HIV for susceptibility towards IHL. The 
quantitation of viral results were carried out on a spectrophotometer and a second generation 
tetrazolium dye (XTT) was used. The results showed that approximately -3.29 dilution of the 
aqueous extract did not protect cells. On the contrary, it proved to be toxic to both uninfected and 
infected cells. Moreover at low doses the extract demonstrated 50% protection towards 
uninfected cells. 
The third objective entailed the assessment of reproducibility of IHL that is routinely 
prepared by the Traditional Health Practitioner (THP). Batch to batch reproducibility is always a 
concern especially since traditional medicine is manufactured without any traceable set of 
standards. Two IHL samples that were prepared on different dates were assessed. Using a thin 
layer chromatography (TLC) a striking resemblance in the two samples was established visually 
by way of fractions produced. However, since TLC is a qualitative tool, it was incumbent that an 
instrument that doesn’t separate sample’s chemical constituents was used. The results produced 
by nuclear magnetic resonance (NMR) confirmed similarities in the two batch of IHL samples 
produced on different dates as it was the case with TLC. Peak intensity and the number of peaks 
in the chromatogram was a mirror image of the other thus confirming consistency in IHL 
preparation. 
The susceptibility tests of IHL towards viruses, bacteria and fungal pathogens present 
reasons why IHL is regarded as a non-specific repressor of pathogens people living with AIDS 
(PLWA) present with. The fourth objective of the study entailed the establishment of active 




and their analysis was carried out on an Ultra Performance Liquid Chromatography Mass 
Spectrometer (UPLC-MS). The substances thought to be responsible for antimicrobial activities 
included:- thalebanin B, methyillukumbin A, kuguacin J, mauritine H, 2-methyl-3-(piperidin-1-
yl) naphthalene-1,4-dione, isoferuloyllpeol, diosindigo A, kuguacin R, verbascoside, kuguacin B 
and nuciferin. Further confirmation studies are needed on fractions to identify their chemical 
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Infection with Human Immunodeficiency Virus (HIV) an etiologic agent of the Acquired 
Immune Deficiency Syndrome (AIDS) is a global phenomenon (Gurib-Fakim, 2006). 
AIDS can be described as a complex array of disorders due to deterioration of the 
immune system caused by the HIV leading the individual being susceptible to 
opportunistic infections and tumours (Marx, 1982). HIV targets the immune system 
especially macrophages and helper T cells wherein proliferation takes place before 
dispersal into new viral host. During viral replication the immune system is severely 
damaged by production of new virions and more so with every infection hence millions 
of new virions are produced each day. The production of antibodies and T cells to fight 
infections remains ineffective against the rate of viral production with subsequent 
appearance of cancer associated with AIDS and secondary opportunistic infections 
(Gurib-Fakim, 2006).  
 
Current treatment options be it orthodox drugs or even vaccines do not cure AIDS, 
however, retards its progression. Previous studies attribute antimicrobial activities to 
secondary metabolites. At present from 36 000 extracts that have been screened by the 
National Cancer Institute of USA, approximately 3600 displayed anti-HIV activity 
(Gurib-Fakim, 2006).  
 
Traditional medicine practice is most prevalent amongst South African population for 






1997). Natural products have become the subject of intense investigation recently in 
relation to conservation and as to whether their application are supported by their 
intended pharmacological effects or merely based on tales of the ancient (Cunningham, 
1988; Locher et al, 1995; Williams, 1996). Undoubtedly traditional medicine’s 
application is quickly gaining momentum as an alternative means of health care. Hence 
there is a need to screen medicinal plants for activity. The purpose of this study was to 
investigate South African medicinal plant product known as Ihlamvu laseAfrika (IHL) for 
potential antimicrobial activity by preliminary bioassay screening and metabolites 
profiling.  
 
The dissertation is written such that each chapter explores antimicrobial properties of IHL 
on a specific organism/s. There are three sections/chapters such as literature review 
(Chapter 2), Chapter 3 (investigated secondary metabolites possibly responsible for the 
aforementioned antimicrobial properties) and Cytotoxicity assay on Chapter 4 which are 
the only exceptions. However, Chapter 5 investigated antiherpes properties of our test 
substance. In chapter 6 the antifungal properties of the test substance were also 
investigated. Cryptococcus neoformans and Candida albicans were two microorganisms 
tested for IHL susceptibility. Antimycobacterium properties tested on MTB strain with 
two techniques such as 1% proportion method and agar dilution was covered on chapter 
7. In chapter 8 the anti-HIV properties were the last susceptibility assay to be explored. 








Briefly the study aimed at investigating the following IHL properties:- 
(a) anti-HSV  
(b) antifungal (C. albicans and C. neoformans)  
(c) antimycobacterial tuberculosis (MTB) 
(d) anti-HIV and 
(e) chemical profile of essential compounds possibly responsible for antimicrobial 





































2.1.1 What is traditional medicine? 
 
The World Health Organization (WHO) gave the following definition to African 
traditional medicine: 
 
“The sum total of all knowledge and practices, whether explicable or not, used in 
diagnosis, prevention and elimination of physical, mental, or societal imbalance, and 
relying exclusively on practical experience and observation handed down from 
generation to generation, whether verbally or in writing” (WHO, 2008). 
 
This definition sets an immediate distinction between science-based approaches to 
treatment to the traditional way. According to Steinglass (2002), an African approach 
to healing is holistic such that an ill person‟s spiritual and physical well-being are 
simultaneously treated. According to Ayurveda and Traditional Chinese medicine 
(TCM) systems, the focus is also on the affected individual rather than on the disease 
(Patwardhan et al, 2005). Alternately, the science-based approach or biomedicine 
would label traditional medicine as phytotherapy. Hence, the medical anthropologists 
would associate traditional medicine and its practitioners with ethnomedicine 
(Nitchter, 1992). Nevertheless, practitioners of medicine are generally subdivided into 
diviners (mediums) and healers (Joles et al, 2000; Steinglass, 2002). Diviners 





provide medicines (Jolles et al, 2000). Healing is approached as a calling that is 
passed down from generation to generation and it would turn into a family business 
(Pujol, 1990; Liu, 2005). However, only one individual within the family would 
receive the gift also referred to as “isikhwama” – the bag. Direct translation takes 
away the essence to description since the bag is rather a trust that becomes a closely 
guarded secret. Scientific studies simply tap into isolating or perhaps modify the 
plant‟s active compounds (Gilani et al, 2005; Patwardhan, 2005; van Vuuren, 2008). 
Research into traditional medicine is done in a bid to further add into the information 
pool hence setting a stage to a more novel entity discovery. More therapeutics are 
necessary in the midst of drugs shortage inadvertently attributed to drug-resistance 
especially seen with Acquired Immunodeficiency Syndrome (AIDS) and treatment 
defaults patients.   
 
The abolishment of the traditional medicine practice by the colonial and apartheid 
regimes in South Africa altered a cultural landscape setting up a platform through 
which sadistic practices by some charlatans under the banner of traditional medicine 
also flourished. The two legislations, the Witchcraft Suppression Act of 1957 and 
Witchcraft Suppression Amendment of 1970 vehemently prohibited traditional health 
practices, however its abolishment could be backtracked to 1891 (Jolles et al, 2000). 
Meanwhile the encroachment of western healthcare system nullified its competition 








2.2 Benefits of Traditional Medicines 
From prerecorded history until recently, southern African people especially the rural 
and peri-urban dwellers would mostly derive health benefits, nutrition and material 
resources from indigenous plants (Pujol, 1990). Health challenges which include 
coughs, wounds, cuts and abrasions, intestinal and gut disorders, migraine, skin 
infections, snake and insects bites etc have been managed with natural product be it 
fauna or flora based products. (Pujol, 1990; Liu, 2005). 
 
2.3 Plant-derived drugs 
Medicinal plant products including their derivatives and analogs contributed over 
50% of clinically used drugs in which 25% of that total is a contribution from higher-
plants (Balandrin et al, 1993). According to folklore, records sampled from several 
cultures around the world, give crucial leads to active therapeutic properties (Bohonos 
et al, 1966; Swain, 1972; Goldstein et al, 1974; Lewis et al, 1977; Balandrin et al, 
1985; Duke et al, 1985; Balandrin et al, 1988; Tyler et al, 1988; Kinghorn, 1992; 
Kinghorn, 1993).  
 
Paclitaxel (also called Taxol®) is a classic example of a plant derived drug that is 
commercially available. It was discovered in 1982 from Pacific yew and is presently 
used as a refractory ovarian cancer drug (Cragg et al, 1993). Paclitaxel is a taxane 
diterpenoid. Etoposide is another example of a semisynthetic antineoplastic agent that 





constituent (Balandrin et al, 1993). The mayapple plant (Podophyllum peltatum L.) 
species is applied in chemotherapy for refractory testicular cancer treatment, small 
cell lung cancer, nonlymphocytic leukemias and non-Hodgkin‟s lymphoma (Horwitz 
et al, 1977; Cabanillas, 1979; Issell et al, 1979; Radice et al, 1979; Budavari et al,, 
1989; Hussar, 1984). Atracurium besylate adds to the list of new plant derived drugs. 
It soothes skeletal muscle and it is both structurally and functionally closely linked to 
curare alkaloids (Budavari et al, 1989; Hussar, 1984). The Δ
9
-tetrahydrocannabinol is 
a drug that is derived from Cannabis sativa L. commonly known as marijuana plant 
or dagga and has found useful application in cancer chemotherapy (Duke et al, 1985; 
Budavari et al, 1989; Anon, 1985). Furthermore, a steroid called digitoxin that is 
derived from Digitalis purpure L. plant and Digitalis lanata Ehrhart (foxgloves) is 
used clinically as cardiotonic glycoside. Opium which is an alkaloid also known 
clinically as codeine or morphine, is derived from Papaver somniferum L. and is used 
for pain management. The second commercially available alkaloid drug is reserpine 
which is extracted from Rauvolfia serpentia L. (East India snakeroot) is used as an 
antihypertensive psychotropic drug. The third alkaloid drug is vinblastine or 
vincristine which is derived from Caranthus roseus L. (Madagascar rosy periwinkle) 
plant and is used as an anticancer drug. Physostimine is a forth alkaloid drug taken 
from Physostigma venenosum Balfour (Calabar bean) and it functions as a cholinergic 
or a parasympathomimetic drug. Another plant-derived drug that acts as a 
parasympathomimetic is pilocarpine which is derived from Pilocarpus jaborandi 






Furthermore there is an antimalarial and cardiac antiarhythmic drug known as quinine 
or quinidine that is manufactured from Cinchona species whose bark is richly filled 
with alkaloids. Other than synthetic drugs, gout has been treated with a plant-derived 
drug called colchicine. Colchicine comes from the Colchicine autumnale L species. 
Another drug which is used as a recreational drug besides marijuana and morphine is 
cocaine. Cocaine is derived from the leaves of Erythroxylum coca Lamarck and its 
intended function was to find application as a local anesthetic. (Lewis et al, 1977;  
Tyler et al, 1988; Farnsworth, 1973; Farnsworth et al, 1976; Farnsworth, 1977; 
Farnsworth et al, 1977; Farnsworth, 1966). The last but not least alkaloid drug is d-
Tubocurarine, another drug for soothing muscles that is derived from plant such as 
Strychnos toxifera Bentham and Chondodendron tomentosum Ruizet Pavon (curare) 
(Budavari et al, 1989; Hussar, 1984).  The Chinese developed Qinghaosu also known 
as artemisinin drug which acts as an antimalaria agent and it is taken from Atermisia 
annua L. plant (Klayman et al, 1984; Klayman, 1985; Nair et al, 1986). There are 
also compounds such as organosulphur that were investigated from plants such as 
garlic and onions for their potential utilization as cardiovascular agents (Block et al, 
1984; Block , 1985) as well as ellagic acid, p-carotene and vitamin E (tocopherol) 
that were investigated for further usage as prototype antimutagenic and anticancer 
properties (Budavari et al, 1989). 
 
Secondary metabolites have in some cases been used as models or templates through 
which absolute synthesis of new drug entities were based. These entities include 





opiates (examples are codeine and morphine), papaverine, salicyclic acid were all 
derived from these models. Another class feature includes anticholinegernics, 
anticholinesterases, antimalaria agents, benzoicaine, procaine, lidocaine (xylocaine), 
and local anesthetics, analgesics (Talwin), propoxyphene (Darvon) methadone and 
mereperidine, verapamil and aspirin (acetylsalicyclic acid) (Lewis et al, 1977; Roche, 
1977; Cassady et al, 1980; Gund et al, 1980).  Similarly in the Unites States (US) the 
furanochromone analogue that is derived from Ammi visnaga (L.) Lam fruit which 
was commercialized as bronchodilator and coronary medicine led to sodium 
chromoglycate synthesis also referred to as chromolyn sodium. Chromolyn is 
currently marketed as a bronchodilator however the main advantage with chromolyn 
is its antiallergenic properties (Sneader, 1985). In a similar example, the galegine 
alkaloid also an active ingredient of Galega officinalis L. was clinically prescribed for 
diabetic patients. However, due to its toxicity to humans, several compounds 
synthesized led to metformin which is structurally and pharmacologically similar to 
galegine and thus is used as an antidiabetic drug (Sneader, 1985). Hence the 
abovementioned secondary metabolites illustrate the importance of traditional 
medicine, their secondary metabolites, especially the active principles, and the role 
they play in modern drug synthesis.   
 
2.4 Treatment with traditional medicine 
According to African tradition, diseases are believed to be inflictions from 
supernatural beings, through spiritual, entities or ancestral spirit, living people, 





one‟s life coupled to a host of misfortunes. Sacrificing of animals, and administration 
of some medicinal plants that are specially formulated by well renowned healers, help 
restore normality (Kale, 1995). It is important to note that THPs treat symptoms as 
opposed to disease entity. Healers lack pathology and patterns of diseases progression 
hence they control symptoms (Leung, 2004). Alternately, diseases can also be 
naturally occurring such as sexually transmitted but to manage symptoms even for 
minor breakout can be a daunting task. Failure to do so can lead one to sort counsel 
from the elders however, one has to contend with discipline. Inability to sort out the 
problem, the elders would make reference to a THP who is endowed with signs and 
symptoms who would then apply the appropriate intervention. 
 
Euclea natalensis is shrub that is mostly found inland and the coastal regions or 
generally in southern Africa (van Wyk et al, 1997). Medicines derived from root 
infusions were taken for bacterial infections by indigenous people of southern Africa 
(Watt et al, 1962). However, the plant‟s medicinal properties includes treatment of 
urinary tracts infections, sexually transmitted diseases and dysmenorrhoea. In some 
parts of the country it is used as a “miswak” or toothbrush (Stander et al, 1991). The 
indigenous people of KwaZulu-Natal, use the root portion for Tuberculosis (TB)-
related symptoms which include, bronchitis, pleurisy and asthma (Watt et al, 1962). 
Activity of this plant is attributed to secondary metabolites for example, the 
naphthoquinones, dihydroxyursanoic acids (lactones derivatives), triterpenoids and 
tetrahydroxyflavanone arabinopyranoside (van der Vijver et al, 1974, Ferreira et al, 






2.4.1 Use of traditional medicine (TM) to treat Herpes Simplex Virus 
According to World Health Organization (WHO) traditional medicine can either be 
composed of a single plant or a combination of several plants, animals and minerals 
(WHO, 2008). In order to manage Herpes Simplex Virus (HSV) breakouts, local 
THPs have a wide variety of medicinal plants to choose from, depending on their 
geographic location. Helichrysum aureonitens Sch Bip. (Asteraceae) is one medicinal 
plant that is predominantly found in southern Africa, particularly in KwaZulu-Natal 
region (Hilliard, 1983). According to Meyer et al (1996), an extract of this plant 
would be topically applied to affected areas. Herpes zoster has been treated with 
exudates of H. aureonitens which treated skin infections by topically applying it to 
affected areas.  
 
2.4.2 Use of TM to treat Mycobacterium tuberculosis (MTB) 
To offer  relief from symptoms due to MTB which may include incessant coughing, 
weight loss, loss of appetite and night sweats, the traditional healer may administer 
extracts made from leaf, bark and root of Acacia nilota or Combretum kraussii and 
Euclea Natalensis species to patients (Lall et al, 1999). 
 
2.4.3 Use of TM to treat Fungal Infections (Candida albicans) 
Common infections that are closely linked to C. albicans clinically manifest as 
pseudomembraneous (thrush), erythematous and hyperplastic variants to linear 





et al, 2006). C. albicans is a commensal organism that is not particularly associated 
with morbidity however, upon exceeding one third of mouth and gut flora which is an 
acceptable level to normal hosts, it can intervene with nutritional intake (Fichtenbaum 
et al, 2000). At this point a THP may opt for extracts taken from Tubalghia alliacea 
(Thamburan et al, 2006) of South African origin.  
 
2.4.4 Use of TM to treat Acquired Immunodeficiency Syndrome (AIDS) 
When immunocompromized patients present with clinical symptoms befitting AIDS, 
the most trusted phytotherapeutic agent that is highly recommended would most 
probably be Hypoxis hemerocallidea and Sutherlandia frutescens extracts. The two 
plants extracts were endorsed by the South African Health Ministries in a fight 
against HIV since it displayed extensive immunostimulation properties (SADC, 
2002).  
Treating of symptoms constitute one branch of traditional medicine involving a healer 
(inyanga). The second branch entails seeking the main cause of illness and dispensing 
treatment and it involves a consultation with a diviner (Isangoma). Sangomas would 
diagnose by “throwing bones” which would tell of the past and present and foretell 
the future events (Pujol, 1990). Hence traditional medicine substantially introduces 
intricate relations that unite the living with the unseen and ultimately gives guidance 








2.5 HIV/AIDS treatment options 
As it is observed in treatment of several chronic disorders with traditional 
interventions, a trend is also noticeable in traditional medicine usage against Human 
Immunodefiency Virus (HIV)/AIDS (Sukati et al, 2005; Bodeker et al, 2000; Josephs 
et al, 2007; Manfredi, et al, 1999). The reasons vary from developed to developing 
countries.  
Lack of access to antiretrovirals (ARV)‟s created much dependency towards natural 
products amongst people living with AIDS (PLWA) in order to manage symptoms. 
High cost of drugs also became a contentious issue however as soon as they became 
available, high cost price made them inaccessible due to high levels of 
unemployment. This therefore meant high viral load was to go rampant on the 
resource poor communities (Ivers et al, 2005). This prompted WHO to introduce a 3 
by 5 initiative which essentially meant to ensure that 3 million PLWA would have 
access to ARV‟s by 2005. The initiative was coupled to ARV‟s price reduction 
(Peres-Casas et al, 2001) as a result of the World Trade Organization signing an 
agreement on Trade-Related Aspects of Intellectual Property rights (TRIPs) that 
would ensure increased access to ARV‟s an aid geared for Southern African 
Development Community (SADC) region.  
 
Notwithstanding the aforementioned initiative by the WHO, reliance on natural 
products remained a formidable challenge to the Highly Active Antiretrovirals 
Therapy (HAART) program (Langewitz et al, 1994; Dahab et al, 2008). Media would 





patients on ARVs would terminate HAART regiment only to ensue with traditional 
medicine/complementary and alternative medicine (TMs/CAMs) interventions due to 
perceived lack of side effects. Such statements remain invalid with most TM/CAM 
that have not been clinically tested hence it only remains a marketing gimmick on the 
part of some THPs. When patients suddenly stop taking ARV‟s and switch to TMs it 
becomes a serious life threatening undertaking. The presence of regulatory bodies 
would therefore serve as a deterrent to such a robust and irresponsible marketing 
tactic (WHO, 2005). A combination of both therapeutic agents, TM/CAM and 
HAART has been taken up by another group living with HI virus for viral 
suppression disregarding negative impact this might have on their livelihood and as 
well as the impact of dual therapeutics effect on drug metabolism (Josephs et al, 
2007; Babb et al, 2007; Mill et al, 2005). General studies revealed overwhelming 
evidence that proves drug interaction between two therapeutic agents (Mills et al, 
2004) which therefore prompt for TM-HAART interaction studies to be conducted 
immediately. 
 
2.6 Globalization and Traditional medicine 
With globalization of all human aspects saw floodgates of trade being widely opened 
and information exchange on an increase, traditional medicine has also undergone 
total revolution. The suppressive laws previously used to deny custom practices were 
abolished and governments embraced change and reinstated traditional health 
practices as a right enshrined in the constitution of the land, as the “right to health”. 





Council (eThekwini Local Branch), Mwelela Kweliphesheya & Umgogodla Wesizwe, 
and African Dingaka Association etc freely practiced the trade. Instead of seeing THP 
totally collapsing, traditional medicine made a robust return. It gained momentum 
rather and acquired more attention than previous practices, HIV/AIDS is held 
accountable. Furthermore traditional medicine is a system that is deeply entrenched 
within African culture despite westernization even amongst the youth (Sherrif, 1996). 
Households continue to utilize traditional medicine as a primary health care (Hardon 
et al, 2008). The youth especially those in trouble with the law would seek counsel 
from THP‟s to win major cases. Teenage pregnancy which is most prevalent in 
townships strongly relied on local THPs which prompted government to legalize 
abortion otherwise illegal abortion became another “assisted suicide” in African 
townships. Almost 60% of babies were delivered with the help of local midwives 
(Karim et al, 1994). I would argue however, that traditional medicine utilization is 
presently most prevalent in urban areas as opposed to rural areas. It is cultivated and 
prepared in rural areas but most utilization is found in urban areas. With urbanization 
and globalization of the entire country,   rural areas are becoming obsolete, hence the 
mushrooming of informal settlement in cities which subsequently introduces rural 
practices to major cities including informal trade (Dauskart, 1990).  
 
Job seekers migrate to urban areas for career opportunities whereby THPs would 
dispense lucky charms for career opportunities and recreational medicine to help 
maintain family life (aphrodisiacs). Zimbabweans have coined a term, “Central Lock 





affairs (Mail and Guardian, 2001). It is not unusual on every street corner to observe 
flyers dispensed or pasted on robots advertising services of a powerful healer from 
distant shores. Scales have drastically tilted in favour of traditional practices which 
saw its support rising in scales of 200 000: 25 000, THP‟s vs general practitioners 
(GP‟s) respectively (Karim et al, 1994). Monies injected to boost country‟s economy 
and stimulate job creation through the trade were estimated to 3.4 USD through sales 
of 525 tonnes of plant materials (Mander, 1998; Dold et al, 2002). 
 
Further development which appeals to the trade support includes digital migration 
from word of mouth to most robust marketing tool involving popular gadgets i.e. 
cellphones. Other means THP‟s have employed to reach the masses include the 
internet, newspaper and radio (Bonora, 2001). Local newspapers are richly filled with 
adverts and often disturbing news involving slaughtering for human body part 
constituting “muthi killings”, a practice that is spiraling out of control. “Muthi” 
killings are motivated by numerous factors practiced by dubious characters that seek 
to undermine the trade. Such atrocities are countrywide however they are most 
prevalent in Limpopo, southern KwaZulu-Natal and the Eastern Cape and until 
recently in the Midlands (Pietermaritzburg) judging from publicity in the news. 
“Muthi” simply means a substance that could be of either fauna or flora origins which 
is administered to patients in distress by an experienced THP (Ashforth, 2005). The 
infiltration of traditional health practices with witchcraft (abathakathi) who openly 
advertise such services to public is a disservice not only the trade but to the spirit of 





country‟s constitution. The use “tokoloshes” to fetch money is tantamount to theft 
and robbery. “Tokoloshes” are “small boys like creatures” that are only visible to 
children of tender age which witches use to execute a special task which is usually 
rewarded by spilling of blood (Ndhlala, 2009).  
 
2.7 Research into Traditional Medicine in South Africa 
Southern Africa is home to 30 000 plant species of which 3 000 species have 
medicinal properties (van Wyk et al, 1997). Furthermore, South Africa has culturally 
diverse societies each having unique customs however, despite cultural diversity, 
traditional medicine plays a pivotal role nonetheless. In addition to this, the 
preservation of indigenous knowledge systems that is prevalent through all the 
cultures is oral and it has been incessantly practiced without fail from generation to 
generation (Hutchings et al, 1994; van Wyk et al, 1997). Hence there are currently 
200 000 THP who render services to their respective communities (van Wyk et al, 
1997). Traditional medicine traded annually can be estimated to 20 000 tons. 
Furthermore, the informal trading with traditional medicine at low cost gives the 
practice an added advantage as opposed to the western system (Taylor et al, 2001). 
As a result there are 80% South Africans who derive benefits from use of traditional 
medicines despite the improved availability of orthodox drugs (Shale et al, 1999).  
 
South African botanists have compiled a list of indigenous plant species, however 
critical information related to efficacy and medicinal properties has still been 





traditional medicines that have proved useful over time. China developed a 
pharmacopeia on traditional medicines whereas Germany established monographs 
(Keller, 1991). South Africa compiled a list of medicinal products and their 
constituents, a work done by Nair et al (Nair et al, 2006). Data compiled from 
product is crucial for their commercialization.     
 
Research done on natural products in South Africa focuses both on in vitro, in vivo 
studies as well as on safety and efficacy (Cocks et al, 2002). A new trend is 
developing worldwide that seeks to integrate traditional medicine with primary health 
care (Fennell et al, 2004). 
The streamlining of traditional health practices into mainstream healthcare system in 
South Africa started in the 90‟s post apartheid era. A group of scientists were allotted 
a task of evaluating the health system and the proposed a model (Freeman et al, 
1992).  
 
The period between 1999 and 2006 had had a tremendous research output that 
provided clinical evidence of phytotherapeutic nature. Contribution towards 
knowledge production by South African scientists as witnessed in Journal of 
Ethnopharmacology publications from 1980 to 1994 was c.a 10-20%. However, there 
has been dramatic change in contributions recently; the percentage contribution has 
reached an alarming 55% (Light et al, 2005). Claims made by some THPs that they 
treat HIV/AIDS (City Press, 2001; Mercury, 2000) and their preparedness into 





properties raised a serious curiosity to science communities. The subsequent research 
validated some claims and it was observed that traditional medicines have 
antimicrobial properties. In case of AIDS, it remained to be proven whether TMs 
exerts their activities by inhibiting growth of HIV causing AIDS or indirectly through 
inhibition of microbes causing secondary opportunistic diseases. Some publications 
made by a number of research institutes and laboratories garnered interest into the 
subject, marking growing interest into research of TMs (Hutchings et al, 1994; van 
Wyk et al, 1997). South African government through National Research Foundation 
(NRF) answered a call and made a generous contribution (R15 million/pa) towards 
research into Indigenous Knowledge Systems (IKS) (Mulholland, 2005).  More 
contributions have been received from the international communities such as 
President's Emergency Plan for AIDS Relief (PEPFAR) based in the US. PEPFAR‟s 
mandate is to help in a fight against AIDS, malaria and TB to impoverished nations of 
the world. 
 
According to statistics less than 5% investigations have been conducted regarding 
“plants and antimicrobial” of South African origins (table 2.0), according to Scopus 
and Science Direct. Hence more research is required for knowledge production 
especially in the field of antimicrobial properties, otherwise South Africa research 








Table 2.0: A display of some prolific authors whose research have been severally 
cited. 
 
Publications    Authors 
Antimicrobials research  van Wyk (2002) 
Antimicrobial Screening Rabe and van Staden (1997); Lin et al, 1999; McGaw et al, 
2000; Kelmanson et al, 2000; Motsei et al, 2003; Eldeen et al, 
2005; Buwa and van Staden, 2006; McGaw and Eloff, 2005 
Antimicrobial Reports Meyer and Afolayan, 1995; Meyer and Dilika, 1996; Meyer et 
al, 1997; Dilika et al, 1997; Afolayan and Meyer, 1995; 
Mathekga and Meyer, 1998; Lourens et al, 2004; van Vuuren 
et al, 2006 
Antimicrobial (STD)   Tshikalange et al, 2005; Lall and Meyer 1999 
Antimicrobial Activities  Eloff, 1999; Martini et al, 2004; Eloff et al, 2005 
MIC    Eloff 1998a 
Chemical Profiling Rabe and van Staden 2000; Drewes et al, 2005; Drewes et al, 
2006 
Antimicrobial   Louw et al, 2002; Lewu et al, 2006 
 
The amount of research done on South African plant species still remains insufficient for 
the World Health Organization to establish monographs upon which guidelines for 
phytotherapeutics could be based upon. 
 
Studies revealed a dramatic increase in traditional medicine usage reaching an 
alarming $60 billion figure the world over (WHO Fact Sheet No. 134, 2008). Further 





Table 2.1: Consumption of traditional medicine per country  
 
Country  TM % Use Annual Spending     Frequency of Use_____________  
China   30-50   N/A   N/A 
Europe   >50   N/A   >1 
North America  >50   N/A   >1 
Dev Countries  >50   N/A   >1 
Germany   90   N/A   >1 
UK    N/A   $320m   >1 
Ghana   60   N/A   >1 
Mali   60   N/A   >1 
Nigeria   60   N/A   >1 
Zambia   60   N/A   >1 
USA   N/A   $150m   >1 
RSA*   75   $76.9m   >1   
 
 (* Food Agricultural Organization, 1998; WHO fact sheet No. 134, 2008, more than 
once is abbreviated: >1). 
 
2.8 Biodiversity and legislation 
Ethno-botanical knowledge has been the source to sizeable drug discoveries (Kartal, 
2007). Over the past plenty of national corporations have exploited indigenous 
resources through which drugs of commercial value have been produced without 
compensating IKS holders for knowledge transferred. Statutory bodies such as 
Conventional of Biological Diversity (CBD) have thus been mandated to assign 
ownership of biodiversity to individuals or community and to accord rights to protect 
this knowledge (Ng‟etich, 2005). 
 
In South Africa an act also referred to as the National Environment Management Act 
(NEMA), the Biodiversity Act of 2004 as set out in the Government Gazette of 2008 






i) To further regulate the permit system since the system applies to bio-prospecting 
that involves any indigenous biological resources or export from the Republic 
of any indigenous biological resources for the purpose of bio-prospecting or 
any other kind of research; 
ii) To set out the content of the requirements and the criteria for benefit-sharing and 
material transfer agreement. 
 
2.9 Intellectual Property Rights 
Whether new products, new technologies or even active compounds are derived from 
use of indigenous knowledge, legislation needs to ensure that those communities who 
have historical guardianship will reap benefits derived from their products or new 
discoveries. The indigenous knowledge holders may have been previously excluded 
on opportunities that realize full value of their indigenous resources but current 
legislation (NEMA) protects and also unlock future benefits in a way that ensures 
sustainable development of the respective communities. Otherwise bio-piracy would 
run unabated. Bio-piracy applies to commercially viable products that are derived 
from traditional knowledge without returns accorded to indigenous knowledge 
holders. This act is rife in developing countries (Udgaonkar, 2004). 
 
The South African government issued explicit definition to IK as set out in the 
Government Gazette No: 30739 issue of 2008 where it is defined as, “indigenous use 
or knowledge” include knowledge of, discoveries about or the traditional use of 





will contribute to or form part of a proposed bio-prospecting or research project to 
which an application for a permit relates.  
 
2.10 Bio-prospecting and legislation 
Bio-prospecting is interpreted as a process whereby local or foreign researchers, 
intentionally seek amongst the wealth of a country‟s indigenous resource, those 
opportunities represented by species‟ and active compounds contained in a species 
which will result in successful commercial exploitation, most often and tragically so, 
outside the country of its origin, an exclusive benefit of a few people unrelated to that 
country (MBB Consulting et al, 2006). 
The NEMA act seeks to act against overexploitation of the countries‟ natural 
resources also whilst ensuring that indigenous knowledge holders reap benefits in 
cases where commercial benefits arise from the utilization of indigenous resources. 
 
2.11 Trends in traditional medicine 
South Africa is one of the countries in the world experiencing an increased usage of 
traditional medicine in recent years as it can be observed on informal street vendors 
and some pharmacies marketing these products. Traditional medicines application is 
widespread (Thring et al, 2006). It is probably because it is firstly a cultural practice 
dating from time immemorial before the encroachment of western system of healing 
and practice. Secondly, the shortage of medical personnel attributed to its widespread 
use. At present there is 1:40000, doctor to patient ratio whereas regarding THPs it is 






Contrary to popular belief, the market for these products is not poverty driven as it 
has been reported elsewhere but accessibility and affordability dictate trends instead 
(Mander, 1998). Sales volume of these products proves it to be a very lucrative 
although informal business. The Eastern Cape is one of low socio developed region in 
South Africa. People in this region rely on traditional medicine mostly for diseases 
treatment as well as personal well-being hence traditional medicine finds most uses in 
this region (Cocks et al, 2002). The annual revenue generated by this sector is 
estimated at R500million. Recent statistical findings have estimated a 54% increase in 
the trade of medicines in this region leading on sales is Hypoxis hemerocallidea 
(African potato) used by people living with AIDS (Dold et al, 2002). Not only has 
this generated much research on African potato but to traditional medicine at large 
and South Africa is also one of the leading researchers (Light et al, 2005). 
 
The THP Bill remains South Africa‟s health initiative to curb the scourge of AIDS. 
The SADC leaders also adopted and ratified a health strategy in a fight against AIDS 
(Baleta, 1998). The collaborative work began to see THPs acquiring skills such as 
educators, counselors and disseminate information on HIV and STI‟s to their 




2.12 Safety assessment of Traditional Medicines 
 
General safety evaluation in traditional medicine is purely based on the long historical 





regime. As a matter of fact this is a turning point in traditional medicine history 
because the two acts enacted, Witchcraft Suppression Act of 1957 and Witchcraft 
Suppression Amendment Act of 1970 explicitly prohibited traditional healing 
practices (Jolles et al, 2000). Ironically the trade now suffers hangover from past 
degradation seeing that it now often carries horror stories associated to witchcraft that 
further tarnish the trade by the very people who are supposed to benefit from it. This 
explains the secrecy even unto the level of consumers benefiting from these aids 
(Martin-Facklam et al, 2004). This makes data collection impossible especially for 
treatment efficacy studies. 
 
The increased research on TMs/CAMs saw WHO Western Pacific region stipulating 
guidelines to follow for safety and efficacy evaluation (WHO Western Pacific region, 
2008). Many countries seem to display a serious lack of vigilance with regards to 
traditional healthcare practices due to unstructured regulatory bodies (Schilter et al, 
2003; Bast et al, 2002). A comprehensive approach towards the subject should cover 
the following viz:- medicinal usage,  chemical data, toxicological studies, 
pharmacological studies, intervention trials, epidemiological studies, patients 
profiles/case records, and post- marketing surveillance (Schilter et al, 2003). Had 
there been sufficient regulation of TMs/CAMs, post-marketing surveillance could be 
readily available had products been registered. Safety and efficacy on commonly used 
natural products, especially in developed countries, is accessible via literature (refer 
table 2.0). Hence some aspects such as adverse health risks, side effects and treatment 





adverse reactions on TMs/CAMs were compiled based on fatal cases previously 
reported on some plant products (Steward et al, 1999).  
 
Ihlamvu laseAfrika (IHL) is a polyherbal mixture (courtesy of Baba Thabethe) that is 
regarded as a non-specific growth repressor of pathogens a person infected with 
HIV/AIDS presents with. However, certain factors need careful consideration 
regarding TM intended benefits. Seasonal changes, for example may affect 
pharmacological profile of medicinal plants. These changes can be exhibited within 
changes in the genome, the transcription, expression and post-translation 
modifications of proteins as well as secondary metabolites (Moco et al, 2007). 
Chemical consistency is important in ensuring efficacy and consumer safety (Sahoo 
et al, 2010). In the next chapter, cytotoxicity studies regarding use of IHL would be 
dealt with. The chapter aims at establishing cytotoxicity of IHL on the basic functions 
of the cell that can be quantified relative to levels of cellular damage. The second aim 
serves to determine the safe and effective dose to be used throughout the Glutathione 
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Introduction: New chemical entities with novel mechanism of action that prove useful 
against multi-drug resistant organisms are mostly plant based and they present as 
secondary metabolites (Ballel et al, 2005; Pereira et al, 2005). Plants utilize secondary 
metabolites for protection however, these chemical entities have also been utilized by 
man from time immemorial. Lack of standardized TM preparation, inconsistencies may 
set in and also material used may become extinct. Hence to sustain life certain measures 
need to be taken to preserve and sustain them. 
Objective: To verify batch to batch reproducibility using thin layer chromatography 
(TLC) and nuclear magnetic resonance (NMR) and to profile secondary metabolites 
using UPLC-MS. 
Materials and Methods: Samples E and F would be analyzed with TLC and visualized 
under UV at 254 and 366nm and furthermore confirm with NMR. After establishing 
similarities, one sample would undertake chemical profiling with UPLC-MS. 
Results: TLC established striking similarities with samples E and F. Further resemblance 
was confirmed with NMR. Chemical profiling of IHL enabled establishment of the 
following chemical entities viz:- thalebanin B, methyillukumbin A, Kuguacin J, 
mauritine H, 2-methyl-3-(piperidin-1-yl) naphthalene-1,4-dione, Kuguacin J, 
Isoferuloyllpeol, Diosindigo A, Kuguacin R, verbascoside, Kuguacin B and nuciferin   
Conclusion: It has been proven that IHL possesses antimicrobial properties that could 
possibly be used to manage HIV/AIDS and its secondary opportunistic infections. 







utilized by THPs during their medicinal preparations, consistency within batches 
manufactured on different dates was established. 
 
3.1 Introduction 
3.1.1 Metabolites Profiling (UPLC-MS) and Quality Control (NMR and TLC) 
There is a growing interest and a great potential for drug development from plants (Cox 
et al., 1994; Farnsworth, 1993). This is necessitated by drug resistance experienced with 
current drug interventions especially witnessed with HIV/AIDS and TB patients. 
Resistance however inadvertently exhausts current drug regimen such that new options 
need exploration. New chemical entities with novel mechanism of action that proves 
useful against multi-drug resistant organisms are mostly plant based (Ballel et al, 2005; 
Pereira et al, 2005). 
 
A traditional medicine called IHL that is of anecdotal use by HIV/AIDS patients in 
KwaZulu-Natal province was studied. Plants utilize secondary metabolites for protection, 
however, the secondary metabolites have also found useful role to man although not all 
plants have been researched. Successful screening for antimicrobial activity against test 
plant as well as biosafety assays led to further tests. One of the objectives of this chapter 
is to identify the bioactive components present in IHL that are thought to have 










3.1.2 Secondary metabolites 
Metabolites can be divided into two, namely primary and secondary metabolites. The 
plant primary metabolites are responsible for plant growth and development whereas 
secondary metabolites are species specific such that in tissues, cells they are involved in 
plant development (Verpoorte et al, 2007). To withstand changing seasons, secondary 
metabolites curtail for such changes. As an adaptation strategy, plants have developed a 
complex machinery responsible for abiotic (light, UV, water) and biotic (parasites, 
herbivores and attacks from pathogens) stress factors (Hall, 2006). Furthermore, primary 
metabolites serve metabolic functions (agricultural yields) whereas secondary metabolites 
are responsible for colours, flavours and also circumvent stress factors (Verpoorte et al, 
2007). Moreover, it is secondary metabolites that man derive health-benefits from, 
presented as diospyrins and others in various plant species. In order to establish the type 
of metabolites present, several analytical techniques have been employed. Firstly there is 
“metabolic fingerprinting”. This is high throughput qualitative screening for metabolic 
constituents. Sample preparation and analysis is relatively rapid and it is a simple 
technique. Alternatively, there is “metabolic profiling” technique involving identification, 
quantification of secondary metabolites. To be borne to mind that the data presented with 
this technique represents a “snapshot” of metabolic information confined to time and 
space. Stress factors contribute largely to different expression of different secondary 
metabolites. Notwithstanding the fact that samples taken from different sources can still 
compare however, the conclusion reached should be clearly based on the initial sample 








3.1.3 Analytical techniques applied in secondary metabolites studies 
There are five major techniques that are presently utilized for profiling viz:- H/UPLC-
MS, GC-MS, TLC-UV, MS
n
 and NMR (Verpoorte et al, 2007). NMR and mass 
spectrometers are regarded as the primary tools that can be universally applied. However, 
the two technologies display some distinctive characteristics as well as disadvantages 
considering a wide array of metabolites detected, their resolution and sensitivity 
(Verpoorte et al, 2007). As a result, the current techniques fall short in detecting both 
qualitative and quantitative data presented by all metabolites in tissue extract. Hence, a 
“profile” of a specific group is subsequently identified and quantified if not, “fingerprint” 
of a particular metabolite is subjected to pattern analysis (Ratcliffe et al, 2005). In this 
investigation, the chemical profiling would be carried out on UPLC-MS, hence this 
technique is emphasized. 
 
3.1.4 Quality Control with Thin Layer Chromatography (TLC) 
TLC is one of the important technique used in secondary metabolites studies however, its 
importance is fading with time (Merfort, 2002). This technique however, provides crucial 
information about the type of metabolites present. In order to visualize TLC fractions, 
numerous reagents can be utilized such as vanillin/o-phosphoric acid, anisaldehyde or p-
dimethylaminobenzaldehyde-sulfuric acid, sulfuric acid, resorcin-sulfuric or phosphoric 
acid, aluminium chloride or hydroxyl-amine (Kery et al, 1987; Kelsey et al, 1973; 
Drozdz et al, 1978; Picman et al, 1980; Villar et al, 1984; Nowak, 1993)   
Preliminary TLC screening of two sample batches was done in order to establish 







3.2 The study’s objective: 
1. To verify batch to batch reproducibility with: 
a) Thin Layer Chromatography (TLC) 
b) Nuclear Magnetic Resonance (NMR) 
2. To do chemical fingerprinting of IHL with UPLC-MS 
 
3.3 Materials and Methods 
3.3.1 TLC Chemicals 
1. Methanol, gradient grade (Merck). 
2. Formic acid, spectroscopic grade (Fluka). 
3. Water, triple deionized, from the Milli-Q purification system (Millipore, Bedford, 
MA), resistivity 18.0 MΩ-cm, filtered through 0.2 μm membrane filter. 
4. Acetonitrile, ultra gradient HPLC grade (Merck). 
5. Sulphuric acid (Merck) 
6. Vanillin Spray (Sigma-Aldrich) 
 
3.3.1.1 Sample Preparation and Plate Development 
The two lyophilized products of equal quantities were reconstituted in aqueous medium. 
The two sample assigned labels UKZN-201-12001E and UKZN-201-12001F were 
shortened to E and an F respectively. The two samples were subjected to thin layer 
chromatography (TLC) analysis. TLC is regarded as the simplest and rapid method for 
detecting plant constituents in metabolomics studies. Approximately 5µL of compound 







was hairdryed to eliminate streaking due to aqueous medium. A mobile phase composed 
of (90: 9.5:0.5) chloroform/methanol/acetic acid was used. The plate was furthermore 
sprayed with vanillin (1% alcoholic vanillin and 10% sulphuric acid). For improved 
visualization the plate was heated in the oven for almost 20 minutes at 100
°
C. The plates 
were viewed under UV 254 and 366nm.  
 
3.3.2 Quality Control with Nuclear Magnetic Resonance 600 Varian (NMR) 
3.3.2.1 Principle 
Nuclear magnetic resonance principle is based upon nuclei spin in an external magnetic 
field. In the absence of the magnetic field, there’s a random orientation of nuclei spins. 
However, in case of a strong magnetic field, the nuclei spin is reoriented such that it is 
aligned with the field or against it. Orientation that’s parallel to alignment of applied 
forces has lower energy. When nuclei are irradiated with RF radiation, the lower energy 
nuclei move to high state and it is said to be in resonance, hence the term nuclei magnetic 
resonance. 
 
3.3.2.2 Methods NMR Sample Preparation 
Ten milliliters of methanol-CD3OD (Sigma-Aldrich Grade) were used to rehydrate 
lyophilized products (E and F). Each of the two products was transferred onto NMR 












3.3.2.3 NMR parameters 
The sample analysis was done with an Inova spectrometer operating at 8445.0Hz for 
1
H 
frequency (Varian). Spectra were collected via solvent suppression pulse sequence based 
on one dimensional nuclear Overhauser effect done to saturate residual [
1
H] water proton 
signal (acquisition time - 1.94 min, tof - 1199.4 and tpwr - 54). Transients were collected 




3.3.3 Chemical Profiling with Ultra-Performance Liquid Chromatography-Mass 
Spectrometer (UPLC-MS) 
3.2.3.1 Principle: 
High performance liquid chromatography mass spectroscopy is basically the separation 
of a mixture with HPLC system preferably using reverse-phase column. In such an 
instance, the analyte is ionized with an appropriate ion source by various methods (ESI or 
electron spray ionization, APCI or chemical ionization under atmospheric pressure or in 
multi-mode source by various methods) followed by partial fragmentation. Soon after 
acceleration they are deflected by a magnetic field which resolves them according to their 
mass. 
 
3.3.3.2 UPLC-MS: Instrumentation and Software 
The UPLC-TOF-DAD-MS system: UPLC Waters Acquity instrument was coupled to an 
Acquity DAD (diode array detector) and a Synapt HDMS detector (tandem 
Time-of-flight mass spectrometer). The mass spectrometer detector used an electrospray 







ionization modes. An aquity UPLC BEH C18 column of 1.7µm particle size and 
1.0X50mm column dimensions, with a column pre-filter were used. The system used the 
MassLynx 4.1 instrument software (Waters).An XCMS program for mass peaks 
extraction and alignment is an incorporated program used for data analysis. 
 
3.3.3.4 Sample Preparation 
Random collections of fresh samples from a traditional healer took place on different 
dates and these were tested for consistency. From each batch a sample was aliquoted into 
50mL centrifuge tube, filtered through a 0.22µm PTFE filters and labeled. Quality checks 
of the two aqueous samples labeled UKZN-201-12001E and UKZN-201-12001F were 
done on Ultra Performance Liquid Chromatography- Time of Flight- Diode Array 
Detector-Mass Spec (UPLC- TOF-DAD-MS).  
3.3.3.5 The UPLC parameters 
There was a 30 minutes sample runtime. The system mobile phase was set as discussed 
above. A sample injection volume of 1µL was used.  The pump flow rate was 
0.3mL/min. The temperature of an autosampler was set to 12
◦
C. The column temperature 
was set to 35
◦
C. The injection needle washed with 200µL of the strong needle wash 
solution and 600µL weak solution. The column was equilibrated for at least an hour 
before use. 
 
3.3.3.6 Diode Array Detector 
The diode array (DAD) detector was connected in series with Synapt HDMS that was 







complemented the MS with regards to compounds identification. An Acquity UPLC 
DAD detector was operated within 220 to 500 nm range. 
 
3.3.3.7 Time of Flight (TOF) parameters  
The TOF was operated in the V-mode at a high mass resolution. Spectral acquisition was 
set from 100 to 1000 m/z with no preset target with scan duration of 0.4 sec. The MS 
parameter were set such that the capillary voltage was 3.2kV, cone voltage 35kV, source 
temperature 120
◦
C, the source temperature was 120
◦
C and the desolvation temperature 
300
◦
C. Nitrogen had a flow rate of 25L/h. 
 
3.3.3.8 High Resolution Mass Spectrometry (HRMS) 
The high resolution mass spectra could be found on a Micromass-LCT Premier Time of 
Flight (TOF) mass spectrometry (Waters, MA, USA). It is normally equipped with an 
electronspray interface hence it also sometimes referred to as High Resolution 
Electronspray Interface Mass Spectrometry (HRESIMS) which is coupled to an Aquity 
UPLC-MS (Waters, MA, USA).  The electronspray interface conditions are as follows: 
Voltage: 2800, Cone voltage: 40V, MCP Detector voltage: 2650V, Source temperature 
120
◦
C, Desolvation gas flow: 550 l/h, Desolvation temperature 250
◦
C, Cone gas flow: 10 
l/h. Both positive and negative modes were used for detection in m/z range of 100 to 










3.4 Results and Discussion 
3.4.1 Batch-to-batch reproducibility with TLC 
In order to ensure sample reproducibility for every batch of IHL produced, quality control 
check was incumbent. Local traditional practitioners often do not adhere to aseptic 
practices since they have no laboratories. Sample preparations and chemical constituents 
of traditional medicines remain undisclosed thus making important documents such as 
standard operation procedures non-existent. Hence some governments took unilateral 
decision to streamline traditional medicines into the mainstream healthcare system in 
order to regulate them as public entities. That entailed research initiations that would 
amicably introduce policy issues and quality control measures regarding product 
development. A bioassay such as thin layer chromatography (TLC) was amongst the 
techniques adopted for the establishment of batch-to-batch reproducibility, particularly 
for this product. The TLC technique displayed optimal sample reproducibility hence it 











Figure 3.1: Fractions of IHL eluted onto TLC plate a test done to compare sample E and 
F. Batch to batch reproducibility of IHL with this technique revealed strong similarities of 
the two samples denoted by E and F. The two samples were apparently prepared on 
different dates. The letters E and F were conveniently used otherwise the two samples 
were identified as UKZN-201-12001(E) and UKZN-201-12001 (F).  
 
Sample E and F migrated equal distances from the solvent front suggesting that the 
polarities of the two samples to be identical. Furthermore, when the TLC plates were 
sprayed with vanillin, the brownish purple fractions became apparent. The darker the 
sample spot the more concentrated the sample as less UV tends to be more adsorbed 
(Hess, 2004).The bioautographic technique is capable of producing useful data which 







reagents. Major details such as medicinal types used could further be deduced. However, 
it is important to note that TLC is only a qualitative tool (Hess, 2004) hence the 
utilization of NMR which does not separate chemical constituents had to suffice 
(Negussie, 2009). As the samples were loaded onto TLC plate, an identical and clear 
separation of compounds from the component mixtures suggested definite samples of the 
same source.  
 
3.4.2 Batch-to-batch reproducibility with NMR 
Further confirmation test testing for similarity between sample E and F was also carried 
out on an NMR and results were deduced chromatographically.  
 
 







Through visual assessment of the two superimposed sample chromatograms, there 
appeared similar reproducible peak intensity and peak characters, the retention times and 
peaks’ magnitude also concurred with one another (figure 3.2).  
 
NMR technique is an ideal tool for structural elucidation since it does not separate the 
analyte hence it remains reusable. As a result NMR is closely identified as a universal 
detector (Negussie, 2009) and therefore can be ideal for quality control situation. 
The process involving structural elucidation entails an output signal identified as a 
characteristic spectrum which is unique for individual atoms and molecules. NMR is not 
quite sensitive such that a substantial amount of a sample (> 1mg of 1000Da substance) is 
needed for structural elucidation (Neuhof et al, 2005). Another major setback with NMR 
is its inability to detect low abundant molecules and subsequent detection of 
stereochemistry. Hence, for effective utilization of NMR it has to be supported by mass 
spectrometers and chiral chromatography tools (Neuhof et al, 2005). Important data that 
is incumbent for structural elucidation is based on homonuclear NMR, heteronuclear 
NMR, HMQC-TOCSY and HMBC variables. The homonuclear NMR would provide 
details on spin characteristics hence it grouped together parts of molecule. Heteronuclear 
NMR would furnish with fingerprint details of a molecule thus provide data on 
multiplicity. A HMQC-TOCSY would put together particularly the spin details with 




C, COSY, HMQC and HMBC 
would determine the compound which would eventually be conferred to mass 








The reproducibility of the prepared samples was excellent and the NMR spectral analysis 
of these samples suggested they share the same grouping, spins, bonds and subsequently 
structures that characterize secondary metabolites to be revealed in UPLC-MS chemical 
profiling. The 
1
H-NMR revealed all characteristic resonances for both E and F samples of 
IHL. The high resolution mass provided by homonuclear NMR is ideally suited for 
molecular weight higher than 800 otherwise results tends to be ambiguous. The 
molecular weights (221 - 656) for active compounds of IHL did not contradict one 
another. 
 
In conclusion, NMR was shown to represent a rapid and effective technique for the 
characterization of complex mixtures similar to that of IHL. There was an apparent ease 
of detection of many compounds that were present in different amounts, with relatively 
less and quick sample preparation. 
 
3.4.3 Chemical fingerprinting with UPLC-TOF-DAD-MS 
Having established similarities of the two samples, one of them (samples E) was 
submitted for chemical profiling and the chromatogram generated is shown. Furthermore 
snapshots of individual peaks constituting the chromatogram were highlighted. The 
chemical fingerprints were generated by highlighting the apex of individual peak and 
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Figure 3.3: Chromatogram representing 12 major peaks of IHL as identified on the 


























Compound 1  
 
Name:      Thalebanin B 
Synonym(s):  3-Methylbutanoic acid N-methyl-N-(2-
phenylethenyl)amide.  
Molecular Formula:    C14H19NO 
Molecular Weight:     217.310   
Accurate Mass:     217.146664 
Percentage Composition:    C 77.38%; H 8.81%; N 6.45%; O 7.36% 
 
HRESIMS m/z 217.0789, [M]
+









Compound 1: The high resolution mass spectrum HRESIMS in positive mode provided 
a pseudomolecular ion at m/z 217.0789 [M]
+
, calculated for C14H19NO, 217.1467. The 
deduced molecular formula of C14H19NO corresponds to the pseudo-molecular ion of 
compound 1 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 
literature, this molecular formula corresponds to that of several Thalebanin B, a glycomis 




Figure 3.4.1: Proposed structure of Thalebanin 
 
 
Thalebanin B is a one of the secondary metabolites found present in IHL. Thalebanin is 
a new phenethyl/styrylamine-derived amide isolated from lipophilic leaf extracts of 
Glycosmis cf. mauritiana, Glycosmis cf. cyanocarpa, and Glycosmis crassifolia. 
Thalebanin B extraction from dried leaves was first carried out with EtOAc and later 
purified with EtOAc in hexane. Thalebanin B displayed significant antifungal as well as 
insecticidal activity against Cladosporium herbarum and Spodoptera littoralis, 


























Molecular formula:     C16H17NO2  
Molecular mass:    255.2914 
Accurate mass:     255.3142 
HRESIMS m/z   256.322 [M+H]
+
, (calculated for 
C16H18NO2, 256.322) 
 
Compound 2: The high resolution mass spectrum HRESIMS in negative mode provided 
a pseudomolecular ion at m/z 256.322 [M+H]
+
, calculated for C16H18NO2, 255.322. The 
deduced molecular formula of C13H17NOS corresponds to the pseudo-molecular ion of 
compound 2 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 







yl) naphthalene-1,4-dione, a naphthoquinone that was isolated from E. natalensis plant 
(Mital et al, 2010). 
 
 
Figure 3.5.1: Proposed structure of 2-methyl-3-(piperidin-1-yl) naphthalene-1,4-dione 
 
2-methyl-3-(piperidin-1-yl) naphthalene-1,4-dione: A new in vitro technique utilized 
for antimycobacterial tuberculosis screening for new drug research and development was 
carried out on Tuberculosis antimicrobial acquisition and coordination facility 
(TAACF)(Collins et al, 1997). When anti-MTB agent recorded IC90<10mg/mL, it was 
considered active. 2-methyl-3-(piperidin-1-yl) naphthalene-1,4-dione displayed 
antitubercular activity within 2.40 to 10.88mg/mL range (Mital et al, 2010) This 
compound isolated from E. natalensis plant (Mital et al, 2010), constituted one of active 























Name:      Kuguacin B 
Synonym(s):      3,25-Dihydroxycucurbita-5,23-dien-7-one.  
Molecular Formula:     C30H48O3 
Molecular Weight:     456.707 
Accurate Mass:     456.360345 
Percentage Composition:    C 78.90%; H 10.59%; O 10.51% 
Physical Description:     Crystal. 
HRESIMS m/z   479.3511 [M+Na]
+
, (calculated for 
C30H48O3Na, 479.3501). 
 
Compound 3: The high resolution mass spectrum HRESIMS in negative mode provided 
a pseudomolecular ion at m/z 479.3511 [M+Na]
+








The deduced molecular formula of C30H48O3 corresponds to the pseudo-molecular ion of 
compound 3 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 
literature, this molecular formula corresponds to that of several Kuguacin B, a 
cucurbitacins that was isolated from Momordica charantia, (Chen et al, 2008). 
 
 
Figure 3.6.1: Proposed structure of Kuguacin B  
 
Compound 3: Kuguacin B is one of the five potentially bioactive cucurbitacins that was 
extracted with MeOH from the root of Momordica charantia L. that proved to possess 
anti-HIV properties. The study was done in Yunnan, China by Chen and co-workers 
utilizing indigenous Momordica charantia L. species. An in vitro investigation into anti-
HIV properties of Kuguacin B on C8166 cells however revealed weak anti-HIV activity 
(EC50= 12.08µg/mL), its selectivity index and cytotoxicity were both 30.9 and 



















Compound 4  
 
Name:      Kuguacin R 
 
Synonym: 5β, 19-epoxycucurbita-6,23-diene-3 β, 
19,25-triol 
Molecular Formula:     C30H48O4 
Molecular Weight:     472.707 
Accurate Mass:     472.35526 
Percentage Composition:    C 76.23%; H 10.23%; O 13.54% 





Compound 4: The high resolution mass spectrum HRESIMS in negative mode provided 
a pseudomolecular ion at m/z 472.3553 [M-Na]
-
, calculated for C30H48O4Na, 495.1535. 
The deduced molecular formula of C30H48O4 corresponds to the pseudo-molecular ion of 







literature, this molecular formula corresponds to that of several Kuguacin R, a 
cucurbitane triterpenoid that was isolated from Momordica foetida Schum (Mulholland et 
al, 1997).  
  
Figure 3.7.1: Proposed structure of Kuguacin R  
 
Kuguacin R is cucurbitane triterpenoid compound that was isolated from Momordica 
charantia (Chen et al, 2009). 407mg, 0.000457% fraction obtained over silica gel CC 
were achived with CHCl3/MeOH from 40:1 to 20:1 and MeOH/H2O in 60:40 to 75: 25 
ratios and then Sephadex LH-20 (MeOH). Kuguacin B together with three other 
cucurbitans displayed antiviral activity in vitro that was measured at 23.7µg/mL. The 
selectivity index (IC50/EC50) and cytotoxicity were both 8.4 and >200 µg/mL, 
respectively (Chen et al, 2009).  It was noticed that some literature cited in this work 

























Name:       Methylillukumbin A.  
Molecular Formula:     C13H15NOS 
Molecular Weight:     233.334 
Accurate Mass:     233.087434 
Percentage Composition:  C 66.92%; H 6.48%; N 6.00%; O 6.86%; S 
13.74% 
HRESIMS m/z 239.0580 [M+6H]
+
, (calculated for 
C13H21NOS, 239.134234) 
 
Compound 5: The high resolution mass spectrum HRESIMS in negative mode provided 
a pseudomolecular ion at m/z 239.0580 [M+6H]
-
, calculated for C13H21NOS, 
239.134234. The deduced molecular formula of C13H15NOS corresponds to the pseudo-
molecular ion of compound 5 in the UPLC/UV/ESIMS analysis of the aqueous extract. 











Figure 3.8.1: Proposed structure of Methylillukumbin A  
 
Compound 5: Methylillukumbin A is active principle that was isolated from Glycomis 
mauritiana. The isolated fractions of G. mauritiana prepared with Et2O in hexane, 
displayed antifungal characteristics according to a study that was done in Sri Lanka 
(Greger et al, 1996). The study further revealed that all amides derived from 
methylthiopropenoic acid that were joined to styryl were strongly antifungal than 
phenethyl-amine. The flower of this plant was chewed for toothaches and pyorrhea by 


























Molecular Formula:     C18H18O6 
Molecular Weight:     330.337 
Accurate Mass:     330.11034 
Percentage Composition:    C 65.45%; H 5.49%; O 29.06% 
Physical Description:     Amorphous. 
HRESIMS m/z 333.0938 [M+3H]
+
, calculated for C18H21O6, 
333.13374 
 
Compound 6: The high resolution mass spectrum HRESIMS in negative mode provided 
a pseudomolecular ion at m/z 333.0938 [M+3H]
-
, calculated for C18H21O6, 333.13374. 







compound 6 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 
literature, this molecular formula corresponds to that of several 3,5-Dihydroxy-4′,7-
dimethoxyhomoisoflavanone, a homoisoflavonoid that was isolated from Eucomis 
bicolor (Jiang et al, 2007, Bangani et al, 1999, Crouch et al, 1999).  
 
Figure 3.9.1: Proposed structure of 3,5-dihydroxy-4,7-dimethoxyhomoisoflavonone 
 
Compound 6: Homoisoflavonoids such as 3,5-dihydroxy-4,7-
dimethoxyhomoisoflavonone forms a special type of flavonoids that are commonly found 
in Liliaceae family with several biological functions. Homoisoflavonoids have been 
identified amongst family of Liliaceae such as Ophiopogon, Polygonatum, Scilla, 
Eucomis (E. bicolor) and Muscari (Jiang et al, 2007, Bangani et al, 1999, Crouch et al, 
1999). 3,5-dihydroxy-4,7-dimethoxyhomoisoflavonone is amongst several 
homoisoflavonoids that have been extracted with pure hot ethanol by refluxing and it was 
proven to possess several biological function that may include anti-inflammatory, 
antibacterial, antihistaminic, antimutagenic and angioprotective activities (Jiang et al, 
2007). However, homoisoflavonoids have also displayed potential phophodiesterase 
inhibition (Jiang et al, 2007). In Chinese medicine such as Mai-Dong, homoisoflavonoids 
identified from Ophiopogon japonicus are specially featured as clinical tonic drug 















Compound 7  
 
Name:      Anhydrocochlioquinone A     
Molecular Formula:     C30H42O7 
Molecular Weight:     514.658 
Accurate Mass:     514.293055 
Percentage Composition:    C 70.01%; H 8.23%; O 21.76% 
Physical Description:     Amorphous red solid 
HRESISM m/z 537.2826 [M+Na]
+
, calculated for 
C30H42O7Na, 537.2826 
 
Compound 7: The high resolution mass spectrum HRESIMS in negative mode provided 
a pseudomolecular ion at m/z 537.1497 [M+Na]
+
, calculated for C33H54O4 Na, 537.4016). 
The deduced molecular formula of C30H42O7 corresponds to the pseudo-molecular ion of 







literature, this molecular formula corresponds to that of several Anhydrocochlioquinone 
A , a quinone that was isolated from Bipolaris oryzae (Phuwapraisirisan et al, 2007). 
 
 
Figure 3.10.1: Proposed structure of Anhydrocochlioquinone A 
 
Anhydrocochlioquinone A: A study conducted on Bipolaris oryzae led to the discovery 
of new antitumour properties for the first time (Phuwapraisirisan et al, 2007). Amongst 
compounds isolated through bioassay-guided fractionation of the EtOAc, 
anhydrocochlioquinone A was one of the antitumour compounds. Previous studies have 
reported on cochlioquinones as anti-angiogenic agents (Jung et al, 2003) as well as 
antagonists for human chemokine receptor CCR5, the important drug targets of most 
anti-HIV agents (Yoganathan et al, 2004). Cochlioquinones however displayed moderate 
to weak cytotoxicity hence displaying anti-cancer activity which could be achieved either 
via anti-angiogenesis or apoptosis. Nevertheless, cochlioquinone A inhibited 
diacylglycerol kinase enzyme that is crucial for the induction of apoptosis in melanoma 










Figure 3.11: High resolution ESI-TOF-MS spectrum in negative mode 
 
 
Compound 8  
Name:      Kuguacin J  
Synonym (23E)-3b-hydroxy-7b-methoxycucurbita-
5,23,25-trien-19-al 
Molecular Formula:     C30H46O3 
Molecular Weight:     456.707 
Accurate Mass:     456.360345 
Percentage Composition:    C 78.90%; H 10.59%; O 10.51% 
Physical Description:     Crystal (MeOH) 
HRESIMS m/z 477.3603 [M+Na]
+










Compound 8: The high resolution mass spectrum HRESIMS in negative mode provided 
a pseudomolecular ion at m/z 477.1310 [M+Na]
-
, calculated for C30H45O3Na, 477.3603. 
The deduced molecular formula of C30H46O3 corresponds to the pseudo-molecular ion of 
compound 8 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 
literature, this molecular formula corresponds to that of several Kuguacin J, a sterol that 
was isolated from Momordica charantia (Kimura et al, 2005). 
 
Figure 3.11.1: Proposed structure of Kuguacin J  
Kuguacin J: The current drug regiment seems to loose potency when particularly 
managing multidrug resistance especially witnessed in cancer patients who undergo 
chemotherapy (Pitchakarn et al, 2011). Resistance displayed by patients undergoing 
chemotherapy is mainly associated with the overexpression of ATP-binding cassette 
(ABC) drug transporters such as P-glycoprotein (P-gp) that is responsible for effluxing 
drugs from cancerous cells (Anuchapreeda et al, 2002, Larsen et al, 2000, Lehnert, 1998, 
Schoenlein et al, 1992). Pitchakarn and co-workers have previously established that 
Momordica charantia, bitter melon leaf extract (BMLE) could reverse MDR phenotype 
through onsite upregulation of intracellular accumulation of chemotherapeutic drugs. 
Kuguacin J has proved to be the main principle found in BMLE also established that 
enhanced sensitivity to vinblastine and paclitaxel in KB-V1 cells (Pitchakarn et al, 2011) 
through inhibition of drug transport activity of P-gp thereby upregulated onsite 










kuguacin J which was subfractioned with 95% EtOH also inhibited [125I]- 
iodoarylazidoprazosin into P-gp in a dose-dependant manner which signifies that 




Figure 3.12: High resolution ESI-TOF-MS spectrum in positive mode 
 
Compound 9 
Name:      Verbascoside 
Synonym(s):     Acteoside/Kusaginin.  
Molecular Formula:     C29H36O15 
Molecular Weight:     624.594 
Accurate Mass:     624.205425 
Percentage Composition:    C 55.77%; H 5.81%; O 38.42% 
Physical Description:     Yellow powder 








Compound 9: The high resolution mass spectrum HRESIMS in negative mode provided 
a pseudomolecular ion at m/z 623.1489, [M-H]
-
, calculated for C29H35O15, 623.1976. The 
deduced molecular formula of C29H35O15 corresponds to the pseudo-molecular ion of 
compound 9 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 
literature, this molecular formula corresponds to that of several Verbascoside, a phenolic 
antioxidant that was isolated Clerodendrum hirsutum (Cooper et al, 1980, Pardo et al, 
1993). 
 
Figure 3.12.1: Proposed structure of Verbascoside  
 
Verbascoside is an active principle that was isolated from Clerodendrum hirsutum 
species exhibiting antimicrobial properties (Cooper et al, 1980, Pardo et al, 1993). Dirdry 
et al. (1999) discovered antibacterial properties of the same species whereby 
verbascoside proved active against both Gram positive and Gram negative bacteria. The 
study further demonstrated moderate antimicrobial properties against Proteus mirabilis 
and Staphylococcus aureus as wells as to methicilin resistant strains. In southern Africa, 
verbascoside isolated from Clerodendrum  myricoides proved to have antimicrobial 
properties (Cooper et al, 1980; Pardo et al, 1993) and the plant species was particularly 
used by Zulus for snakebites (Watt and Breyer-Brandwijk, 1962). Vasorelaxant 







verbascoside was known for (Chen et al, 1998, Kernan et al, 1998). However it has been 
recently established that verbascoside also bear antiviral activity against both HSV-1/2. 
Verbascoside was extracted from Lepechinia speciosa with ethanol and later fractionated 
with EtOAc: MeOH (6:1) yielding 212mg powder. The concentrations of the compound 
required to reduce HSV-1 and 2 by 50% were 58µg/mL and 8.9µg/mL respectively 
(Martins et al, 2009). 
 




Name:      Quercetin 3-O-β-D-glucopyranoside 
Molecular Formula:     C21H21O12
 
 
Molecular Weight:     465.390 
Accurate Mass:     465.103305 
Percentage Composition:    C 54.20%; H 4.55%; O 41.25% 
HRESIMS m/z  465.1033 [M+H]
+









Compound 10: The high resolution mass spectrum HRESIMS in negative mode 
provided. The deduced molecular formula of C21H21O12
 
corresponds to the pseudo- 
molecular ion of compound 10 in the UPLC/UV/ESIMS analysis of the aqueous extract. 
According to the literature, this molecular formula corresponds to that of several 
Quercetin 3-O-β-D-glucopyranoside, an amide that was isolated from C. infortunatum 
(Roy et al, 1996). 
 
Figure 3.13.1: Proposed structure of Quecertin 3-O-β-D-Glucopyranoside  
 
One compound in our tonic matched a flavanoid identified as Quecertin 3-O-β-D-
Glucopyranoside or 7-O-β-L-Rhamnopyranoside according to an antifungal research 
conducted by Roy et al. (1996).The quercetin flavanoid was isolated from the root of 
C.lerodendrum infortunatum to which the bioassay displayed strong antifungal activity 
when tested against Alternaria carthami and Helminthosporin oryzae at concentrations 
200, 500 and 1000mg/mL (Roy et al, 1996). Furthermore, the methanol extract of the 
root exudate of Rhodolia rosea proved to be active (MIC=50µg/mL) against S. aureus. 
The bioactivity-guided fractionation of the stem of R. rosea yielded gossypetin 7-O-β-L-
rhamnopyranoside as on of the active compound. When antibacterial and anticancer 
(prostate cell line) evaluation were done, this compound displayed inhibitory activity at 
50µg/mL and 100µg/mL concentrations respectively. 7-O-β-L-rhamnopyranoside 






























Name:      Isoferuloyllupeol  
Synonym(s):      3-(3-Hydroxy-4-methoxy-E-cinnamoyl) 
Molecular Formula:     C40H58O4 
Molecular Weight:     602.896 
Accurate Mass:     602.43351 
Percentage Composition:    C 79.69%; H 9.70%; O 10.62% 
Physical Description:     Crystal. 
HRESISM m/z  605.1849 [M+3H]
+
, - (calculated for 
C40H61O4, 605.1849) 
 
Compound 11: The high resolution mass spectrum HRESIMS in negative mode 
provided a pseudomolecular ion at m/z 605.1849 [M-3H]
-
, calculated for C40H61O4, 







molecular ion of compound 11 in the UPLC/UV/ESIMS analysis of the aqueous extract. 
According to the literature, this molecular formula corresponds to that of several 
Isoferuloyllupeol, a triterpenoid that was isolated from Euclea natalensis (Weigenand et 
al, 2004).   
 
 
Figure 3.14.1: Proposed structure of Isoferuloyllpeol 
 
Isoferuloyllpeol: Euclea natalensis revealed one of its active principles extracted with 
ethanol as isoferuloyllupeol together with other triterpenoids. Other compounds such as 
shinanolone, lupeol and betulin that were also extracted with ethanol displayed activity 
(MIC=100µg/mL) against MTB H37RV strain. This compound showed activity when 
tested against Bacillus pumilus at 100µg/mL in which streptomycin sulfate as a positive 
control displayed growth inhibition against bacterial strain at 10µg/mL with the exception 
of Pseudomonas aeruginosa when the radiometric Bactec system was used (Weigenand 


















Name:      Mauritine H        
Molecular Formula:     C33H43N5O5 
Molecular Weight:     589.733 
Accurate Mass:     589.32642 
Percentage Composition:    C 67.21%; H 7.35%; N 11.88%; O 13.56% 
Physical Description:     Cryst. (MeOH/petrol) 
HRESIMS m/z 589.1827 [M]
+
, -(calculated for C33H43N5O5, 
589.1827) 
 
Compound 12: The high resolution mass spectrum HRESIMS in negative mode 
provided a molecular ion at m/z 589.1827 calculated for C33H43N5O5, 589.1827. The 







compound 12 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 
literature, this molecular formula corresponds to that of several Mauritine H, a 
cyclopeptide alkaloid that was isolated from Zizyphus mauritiana (Pandey et al, 1990; 
Tschesche et al, 1977).  
 
 
Figure 3.15.1: Proposed structure of Mauritine H  
 
Mauritine H: Previous studies have revealed the presence of mauritine H that was 
isolated from Zizyphus mauritiana. Mauritine H possesses sedative, analgesic, anti-
inflammatory, hypoglycaemic, antibacterial and antifungal properties (Pandey et al, 
1990; Tschesche et al, 1977). Some of the active compounds isolated in Z. mauritiana 


























Name:      Kaempferol 3-β-D-glucoside.   
Synonym:      Astragalin    
Molecular Formula:     C21H20O11 
Molecular Weight:     448.382 
Accurate Mass:     448.100565 
Percentage Composition:    C 56.25%; H 4.50%; O 39.25% 
HRESIMS m/z 447,0928 [M-H]
-
, calculated for C21H19O11, 
447.0928 
 
Compound 13: The high resolution mass spectrum HRESIMS in negative mode 
provided a pseudomolecular ion at m/z 447,0928 [M-H]
-
, calculated for C21H19O11, 
447.0928. The deduced molecular formula of C24H34O7 corresponds to the pseudo-







According to the literature, this molecular formula corresponds to that of several 
Kaempferol, a flavanoid that was isolated from Clerodendrum infortunatum (Shrivastava 
and Patel, 2007).  
 
Figure 3.16.1: Proposed structure of Astragalin  
 
Compound 13: Astragalin also known as Kaempferol-3-O-Glucoside is an astragalus 
flavanoid that is found in Astragalus corniculatus Bieb, A. vesicarius L, A. ponticus Pall 
all belong to Fabaceae family. Astraguls is particularly used by Bulgarian folk medicine 
as a diuretic for managing hypertension, renal disorder, nervous disease and rheumatism. 
Strong antioxidant activities and immune boosting qualities particularly the renewal of 
immune cells was also observed. Because of the plant’s antimicrobial activities, it finds 
wide application especially to PLWA (Ivancheva et al, 2006). However, other feature 
such as diuretic effect makes it useful to individuals with high blood pressure. Mild 
antiviral activity has been attributed to astragalin however several prominent compound 
including quercetin, luteolin and rutin synergistically enhanced the anticipated health 
benefits (Krasteva et al, 2000). In another study kaempferol was isolated from 


















Name:      Nuciferine 
Synonym(s):  1,2-Dimethoxyaporphine/Sanjoinine E.  
Molecular Formula:     C19H21NO2 
Molecular Weight:     295.380 
Accurate Mass:     295.157229 
Percentage Composition:    C 77.26%; H 7.17%; N 4.74%; O 10.83% 
HRESIMS m/z 295.1572 [M]
+
, calculated for C19H21NO2, 
295.1572. 
 
Compound 14: The high resolution mass spectrum HRESIMS in negative mode 
provided a pseudomolecular ion at m/z 295.1572 [M]
+
, calculated for C19H21NO2, 







molecular ion of compound 14 in the UPLC/UV/ESIMS analysis of the aqueous extract. 
According to the literature, this molecular formula corresponds to that of several 
Nuciferine, a alkaloid from Nelumbo lutea (Nelumbonaceae) and Colubrina faralaotra 
(Rhamnaceae), also from the Araceae, Berberidaceae, Lauraceae, Menispermaceae, 
Papaveraceae, Magnoliaceae and Annonaceae (Watt and Breyer-Brandwijk, 1962). 
 
 
Figure 3.17.1: Proposed structure of Nuciferin  
 
Nuciferin was isolated from Croton gratissimus. Burnt powder bark of C. gratissimus 
was used by Sothos for bleeding gums and leaves mixture for smoking rheumatism in 
patients (Watt and Breyer-Brandwijk, 1962). Nuciferin occurrence is widespread, it has 
also been isolated from (Nelumbo nucifera Gaertn.) leaves, a perennial species that is 
most prevalent in southern China where it is considered as foodstuff (Xu et al, 2011). 
Chinese traditional medicine has applied the species for heat resolution as well as to stop 
bleeding (Kashiwada et al, 2005). Previous studies revealed active alkaloids as some 
useful components with antioxidants (Cho et al, 2003) antimicrobial (Agnihotri et al, 


















Name:      Narcissidine 
Molecular Formula:     C18H23NO5 
Molecular Weight:     333.383 
Accurate Mass:     333.157624 
Percentage Composition:    C 64.85%; H 6.95%; N 4.20%; O 24.00% 
HRESIMS m/z 333.0140 [M]
+
, (calculated for C18H23NO5, 
333.0140) 
 
Compound 15: The high resolution mass spectrum HRESIMS in positive mode provided 
a pseudomolecular ion at m/z 333.1297 [M]
+
, calculated for C18H23NO5, 333.0140. The 
deduced molecular formula of C18H23NO5 corresponds to the pseudo-molecular ion of 
compound 15 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 








amaryllidaceae alkaloid that was isolated from Narcissus poeticus (many other spp. in the 





Figure 3.18.1: Proposed structure of Narcissidine  
 
Narcissidine is an amaryllidaceae alkaloid that was isolated from Narcissus cultivar 
species (Martin, 1987). These types of alkaloids have biological function ranging from 
antiviral (Martin, 1987, Gabrielsen et al, 1999, Ghosal et al, 1988), immunostimulant 
(Ghosal et al, 1984), analgesic (Kametani et al, 1971), antimalarial (Likhitwitayawuid et 
al, 1993) and insect antifeedant (Martin, 1987, Ghosal et al, 1984). In another study, 
narcissidine that was isolated from Narcissus tazetta used to treat JE virus infected mice, 
displayed no difference between control and treated mice which experienced prolonged 

























Name:      Diosindigo A 
Molecular Formula:     C24H20O6 
Molecular Weight:     404.418 
Accurate Mass:     404.12599 
Percentage Composition:    C 71.28%; H 4.98%; O 23.74% 
Physical Description:     Blue needles (petrol) 
HRESIMS m/z 217.1027 [M+H] 
+
, (calculated for 
C24H20O6, 217.1027) 
 
Compound 16: The high resolution mass spectrum HRESIMS in positive mode provided 
a pseudomolecular ion at m/z 217.1027 [M+3H]
+
, calculated for C14H27NO, 217.1027. 







compound 16 in the UPLC/UV/ESIMS analysis of the aqueous extract. According to the 
literature, this molecular formula corresponds to that of several Diosindigo A, a 
naphthoquinone that was isolated from Euclea natalensis (Watt and Breyer-Brandwijk, 
1962).  
 
Figure 3.19.1: Proposed structure of Diosindigo A  
 
Diosindigo A is one of the four naphthoquinones that was fractionated from root 
macerate of Euclea natalensis (van der Vijver, 1975). Furthermore, diosindigo A forms 
one of the isolated compounds from the root bark of Diospyros usambarensis that 
exhibited antifungal and molluscicidal properties (Marston et al, 1984). Death associated 
with the administration of E. natalensis is specifically confined to the utilization of the 


















Table 3.0: Summary of the16 proposed compounds that were identified with UPLC-MS. 
 
Peak   Ret time (min)  M/Z [M]
+
  Assignment 
 
1.  1.19   217   Thalebanin B 
2.  1.9   255 2-methyl-3-(piperidin-1-yl) naphthalene-1.. 
3.  3.4   479   Kuguacin B 
4.  4.38   495   Kuguacin R 
5.  4.58   233   Methylillukumbin A. 
6.  5.6   333   3,5-Dihydroxy-4′,7…. 
7.  9.8   537   Anhydrocochlioquinone A 
8.  10.8   477   Kuguacin J 
9.  12.3   624   Verbascoside 
10.  12.8   465   Quercetin 
11.  15.2   602   Isoferuloyllupeol 
12.  15.5   589   Mauritine H 
13.  17.5   447   Kaempferol 
14.  17.6   295   Nuciferine 
15.  20.5   333   Narcissidine 




denotes a molecular ion  
 
The UPLC-MS system is an alternate method of choice for structural elucidation 
especially when co-eluting contaminants intervene. Although NMR and other chemical 
profiling techniques may suffice, an MS however remains the main tool geared for such 
purposes. Hence the fragmentation patterns or chemical fingerprints that can only be 
achieved in the presence of a high mass accuracy, MS
n
 fragmentation still remains very 
crucial (Technical Report vol 20). LCMS-TOF helps separate analytes from impurities. 
From the MS
n
 data acquired, structural composition and fragment patterns can be 







its utilization of several data analysis techniques that include peak picking, putative 
identification and alignment. Results confirmation was thereby made possible by 
variables such as retention times, mass and intensity that are derived from a full mass 
spectrum of a chromatogram (Negussie, 2009). 
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An investigation into the 













Seasonal changes affect pharmacological profile of medicinal plants. However this is not 
the only factor affecting efficacy, several other conditions such as cultivation, 
manufacturing, marketing and distribution also contribute. Physiological, genetic and 
environmental factors can drastically alter plant’s biochemical content. Secondary 
metabolites are said to be time dependant, storage, drying, extraction, processing, 
handling and managing plant medicine requires skill. Chemical consistency is important 
for ensuring efficacy and consumer safety (Sahoo et al, 2010).  
 
In vitro cytotoxicity assays are useful in that they measure the effect of toxic chemicals 
on the basic functions of cells, and that the toxicity can be measured by assessing cellular 
damage. Chemosensitivity tests are commonly utilized in both research and clinical 
environments to determine the effect of compounds on tumour cells (Mossman, 1983). 
The cytotoxicity tests conducted seeks to establish the dosage that proves deleterious to 
cells using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and 
GSH-Glo which measures intracellular glutathione levels.  
 
Methylthiazol tetrazolium assay is an important colorimetric assay used to assess activity 
of succinate dehydrogenase enzymes that reduce MTT salt. Essentially MTT or a 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide is yellow tetrazolium salt that is 
reduced to purple formazan crystals in viable cells (Mosman, 1983). The MTT assay 
offers a quantitative, convenient method for evaluating cell population’s response to 
external factors, whether it is increased in neither cell growth, nor effect or a decrease in 
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growth due to necrosis or apoptosis (Cooke and O’Kennedy, 1999). In order to assess cell 
viability, formazan measured in treated cells was compared to untreated cells or negative 
control and dose-response curve was produced. 
 
Reduced glutathione (GSH) the most abundant non-proteinthiol, is an antioxidant found 
in eukaryotic cells. Oxidative stress and free radicals can cause a decrease in GSH levels 
either by oxidation or reaction with thiol group. A change in GSH levels is important for 
assessing toxicological responses and can promote oxidative stress, potentially leading to 
apotosis and cell death (Promega, 2007). The GSH-Glo™ is a luminescence-based assay 
for the detection and quantification of glutathione. The assay is based on the conversion 
of luciferin derivative into luciferin in the presence of GSH, catalysed glutathione 
transferase (GST). The signal generated in a couple reactions with firefly luciferase is 
proportional to the amount of GSH present in the sample. The assay generates stable 
luminescent signal and is simple, fast and easily adaptable to multiwall format such as 
96-well plates. This assay can be used for detection and quantification of GSH in cultured 
cells or various biological samples. The GSH-Glo™ Glutathione assay can be applied for 
measuring glutathione levels as an indicator of cells viability or oxidative stress. It can 
also be applied for screening drugs and new chemical entities for their capacity to 
modulate glutathione levels in cells (Promega, 2007).    
In this assay, cyclosporine A (CsA), a positive control was used. Cyclosporine A is an 
immunosuppressive drug that act by binding onto intracellular receptor and inhibit 
cytokines production. The medicinal concentration above that of positive control is taken 
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as a concentration in which cytotoxicity ensues, hence medicinal concentration dosage to 
be used especially in cell culture assay therefore must not exceed that marker. 
 
4.1 Aim of these tests: 
1. To determine cytotoxicity of IHL with regards to safe in vitro dosage and the 
effect of extended exposure. 
2. To determine safe and effective medicinal concentration to be used throughout in 
vitro assays.   
 
4.2 Materials and Methods 
4.2.1 Reagents and Chemicals 
4.2.1.1 Chemicals 
MTT salt was purchased from Sigma Aldrich. RPMI 1640, EMEM and FCS were all 
purchased from LONZA, USA.  GSH-Glo ™ Kit was acquired from Promerga. 
 
4.2.2 Cells 
Vero cells (African Green Monkey) were provided by the Department of Microbiology. 
These were maintained in Minimum Eagle’s Medium supplemented with 10% fetal calf 
serum (FCS). 
 
4.2.3 Plant extracts preparation 
Traditional medicinal extract was filter-sterilized through 0.2µm filter and lyophilized. 
The lyophilized product was weighed out and 1000µg/mL of aqueous extract was made. 
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From the stock solution several working matrix-concentration in a range of 1000, 800, 
400, 200, 100, 80, 50, 20, 10, 1 and 0.1µg/mL were made. 
 
4.2.4 MTT stock preparations 
A 5mg/mL MTT stock was made by dissolving MTT salt in RPMI-1640. The stock was 
filtered through 0.2µm filter and stored in 2-8
°
C. A working solution was further diluted 
ten-folds in RPMI without phenol red. 
 
4.2.5 Cell Viability Assay 
The assay was conducted following Wilson’s MTT instructions. Vero cells were cultured 
in EMEM supplemented with 10% fetal calf serum and incubated in 5% CO2 humidified 
incubator at 37
°
C. When cells became 90% confluent, they were washed three times in 
PBS and trypsinized using trypsin-versene solution. Trypan-blue exclusion was carried 
out in hemacytometer in order to determine viable cells. A 200µL volume cell suspension 
contained an average of 15000 cells and these were added in 96 well microtitre plates and 
incubated until they became confluent. Supernatant was removed and each well was 
treated with 100µL of medicinal extracts of each serial dilution and this was done in 
triplicates. For negative controls only 5% cell culture media was added and incubated. 
After 24 and 48 incubation, the supernatant was removed. Thereafter ten microliter of 
MTT working solution was added to each well followed by another addition of 5% 
EMEM and incubation at 37
°
C for 4 hours. After the incubation period, the supernatant 
was removed and 100µL dimethyl sulphoxide (DMSO) was added in order to dissolve 
formazan crystals and this was furthermore incubated for an hour. The plates were later 
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read on Beckman DU-600 Spectrophotometer at 570nm wavelength and background 
subtraction at 650nm.  
 
4.2.6 GSH Assay 
The GSH-Glo™ reagent was prepared by diluting the Luciferin-NT substrate and 
Glutathione-S-Transferase 1:50 in GSH-Glo™ reaction buffer. Each reaction (well) of a 
96-well plate required 50µLof the GSH-Glo™ reagent; the total volume of the reagent 
prepared was adjusted according to the number of assay wells. The GSH-Glo-™ reagent 
needed to be prepared immediately before use and could not be stored for future use.  
 
The luciferin detection reagent was prepared by transferring the contents of one bottle of 
luciferin detection buffer to the bottle of lyophilized luciferin detection reagent. The 
contents were mixed by inversion several times until the substrate was thoroughly 
dissolved. Each reaction (well) of a 96-well plate required 100µL of the luciferin 
detection reagent meaning the luciferin detection reagent needed to be 2:1 with the GSH-
Glo™ reagent for the reaction to work properly. The luciferin detection reagent could be 





The dye exclusion test was used to determine the number of viable cells present in a cell 
suspension. It is based on the principle that live cells possess intact cell membranes that 
exclude certain dyes, such as trypan blue, eosin, or propidium, whereas dead cells do not. 
In this test, a cell suspension was mixed with dye and it was visually examined to 
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determine whether cells would take up or exclude dye. The effect of the increasing 
concentration of IHL on cultured Vero cell line according to Trypan Blue dye test, 
showed that the extract to have no effect on cell viability following 7, 28 and 48 hour 
incubation with this extract (table 4.0). Phenotypically viable cell presented with a clear 
cytoplasm whereas a nonviable cell had a blue cytoplasm.  
 
Table 4.0: Tabulated trypan blue exclusion test results showing time and dose effect of 
IHL on Vero cell lines.  
 
# Conc in µg/mL % Cell viability in aqueous medium 
  7 Hrs 28 Hrs 48 Hrs 
 control 100±0 100±0 100±0 
1 1 98.9±0.15 99.1±0.49 98.3±0.50 
2 50 99.0±0.31 98.4±1.27 98.6±0.70 
3 100 98.7±0.84 99.3±0.15 98.2±0.50 
 
 
With regards to cytotoxicity results of an aqueous extract of IHL as assessed by an MTT 
assay, it was established that there existed dose dependant activity. An aqueous extract as 
applied on uninfected Vero cell lines displayed an increasing trend of viable cells at 
lower concentration while high concentration decreased cell viability (figure 4.0). This 
trend was also proved to be time-dependant. The highest concentrations proved to be 
cytotoxic after 24hrs of incubation but this cytotoxicity was not shown over 48 hour 
incubation. The percentage cell viability was measured against untreated control. The 
highest concentration displaying cell viability above 80% after 24 hours was at 40µg/mL 
and the minimum concentration displaying cell viability that is less or equal to 50% was 
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obtained at 100µg/mL. After 48 hours the highest cell viability concentration was 































Figure 4.0: The effect of IHL on cell viability using MTT assay after 24 and 48hours 
incubation respectively.  
 
 
Figure 4.1: The effect of IHL aqueous extract’s concentration on GSH-Glo™ level after 
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The GSH assay using higher concentrations of traditional medicine was done to further 
verify the cytotoxicity of IHL on Vero cells. IHL’s effect on antioxidants was shown to 
be dose dependent (figure 4.1) as seen in recordings taken 24 hours post treatment. 
Antioxidants levels were reduced in proportion relative to concentration levels. 
Luciferase was determined in terms of relative light unit (RLU) detected in the measured 
period. Luciferase assay is basically a cytotoxicity assay however its significance was 
made possible by positive control, cyclosporin whose dosage was used to eliminate 
interference without compromising on activity. Hence the presence of cyclosporin is to 
act as a biomarker that determines the extracts’ concentration which once it is exceeded, 
cells start dying. This therefore makes luciferase assay such an important assay as applied 
to crude extract since it apparently addresses the fact that extract can cause non-specific 
reduction in luminescence (some as high as 98% interference) which could lead to 
erroneous interpretation (Shawar et al, 1997). Therefore in all forthcoming cell-based 
assays the safest dosage below that of a positive control is recommended to assess 
susceptibility of an organism (e.g. HSV) to a traditional medicine extract especially IHL.  
 
4.4 Discussion 
The aim of this study was to establish whether an aqueous extract of IHL would prove 
cytotoxic towards human epithelial cell lines as assessed by an MTT and GSH assays. 
The MTT assay tests for metabolic competence as well as assess mitochondrial 
performance (Fry and Hammond, 1993; Freshney, 2000). It is basically a colorimetric 
test that is based on the conversion of yellow tetrazolium bromide (MTT) to purple 
formazan derivative by mitochondrial succinate dehydrogenase in live cells (Mossman, 
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1983). Glutathione assay (GSH) assesses toxicological responses therefore GSH levels as 
expressed in luminescence indicate a number of live cells. 
 
It would have been interesting had the assay been conducted on both infected and 
uninfected cell lines. This is particularly based on the effect of IHL on cell growth 
stimulation which was observed in the 48 hours post treatment assay particularly with the 
MTT assay. The inclusion of both infected and uninfected cells would establish whether 
IHL protects cells meanwhile killing the pathogen as well as to establish the safest dosage 
whereby cells would be preserved while pathogens would be killed. Nonetheless, we 
have established MTT activity on uninfected cell after 24 hours and what became 
apparent was the mitochondrial gradual retarded performance. This retardation was 
increased with an increase in traditional medicine concentration until a 50% decrease 
compared to the control was noted at 1000µg/mL. It is interesting to note that upon 
prolonged exposure of cells to IHL there is a derived health benefits accorded to cells that 
could probably be associated with the presence of flavonoids. In a study conducted by 
Singh et al (2005) on medicinal plants used to manage AIDS-related symptoms it was 
found to be constituted of this compound. Flavonoids contain antioxidants that scavenge 
free radical thus inhibiting tissue damage that is associated with the onset of AIDS. 
Furthermore, after 48 hours post treatment with IHL, the mitochondrial performance was 
significantly increased (30%) generally across all major concentrations i.e. from 
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The most likely mechanism of action of extract includes its ability to scavenger reactive 
oxidative species or alternately, its ability to upregulate endogenous antioxidants levels. 
(Shtukmaster et al, 2010). Shtukmaster et al (2010) used an aqueous extract of Teucrium 
polium to display an ability to augment levels of important intracellular antioxidants. It is 
therefore safe to assume that the mechanism of extracts health benefit could be due to its 
ability to suppress oxidative stress thus strike a balance with endogenous antioxidant 
levels.    
 
The study has proven that cellular integrity is not immensely compromised at low 
concentrations as it was maintained over prolonged periods of exposure of cells to the 




From data acquired, it was concluded that at low concentrations, an aqueous extract of 
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5.0 Abstract 
Introduction: Ihlamvu laseAfrika (IHL) is believed to have positive effects on 
HIV/AIDS patients however, this has not been proven in clinical or laboratory tests. Such 
effects can either be directly due to inhibition of the virus causing AIDS or indirectly by 
inhibition of organisms causing opportunistic infections.  
Objective: To investigate antiviral properties of IHL against Herpes Simplex Virus 
(HSV) and its effect on GSH level. 
Materials and Methods: A crude extract of IHL was lyophilised and reconstituted into 
stock standards that were prepared in either aqueous or solvents (methanol, ethanol, 
acetone, dichloromethane, cyclohexane and ethyl acetate) of differing polarities. 
Amongst the seven solvents used for extraction, the search for best solvent was 
conducted. The viral susceptibility of herpes simplex virus (HSV) towards solvent extract 
of IHL was assessed and quantified with real-time polymerase chain reaction (RT-PCR) 
and minimum inhibitory concentration (MIC) was then concluded.  
Results: The methanol extract displayed the lowest viral yield (Ct = 19, p = 0.2473) as 





Conclusion: IHL has antiviral properties and RT-PCR is the best tool for quantifying 
viral yield. 
Keywords: IHL, reduced glutathione (GSH), cytotoxicity 
5.1 Introduction 
Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) present several clinical 
manifestations to mankind (Greco et al, 2007). The most common HSV-1 infections are 
cold sores and gingivostomatitis (Villareal, 2001). Usually symptoms wean after a week 
of viral shedding in immunocompetent individuals without taking antiviral drugs. 
Alternately, in immunocompromised individuals, life-threatening diseases may occur that 
might prompt infected host to take up antiviral therapy. Serious manifestations may 
present as encephalitis due to virus spreading to the central nervous system (Whitley et 
al, 1998). 
Forty years have passed since the approval of a number of systemic licensed 
antiviral drugs for HSV treatment. These drugs primarily target the viral DNA 
polymerase. The examples of which feature guanosine analogues e.g acyclovir (ACV), 
famciclovir, valacyclovir VCV and ganciclovir, the acyclic nucleotide analogue cidofovir 
and finally the pyrophosphate analogue e.g. foscarnet (Villareal, 2001). The efficacy of 
these antivirals has been limited by development of drug resistance especially witnessed 
with immunocompromised patients if not the recurrence of latent viruses (Field, 2001). 
This therefore necessitates the development of new anti-HSV treatment drugs that will 
prove safe and effective. 
Over the years traditional medicines have played a major role in a fight against 





displaying active leads for potent drug discovery (Kamatenesi-Mugisha et al, 2008). 
Traditional medicine use has become widespread (Thring et al, 2006). Treating human 
infectious diseases with traditional medicines (TMs/CAMs) is prevalent to most countries 
including South Africa, China, India and others. Screening tests done in vitro so far attest 
to presence of potent antiviral activities with no or limited adverse effects (McCutcheon 
et al, 1995; Vlietinck et al, 1995; Namba et al, 1998, Ma et al, 2002; Fernandez-Romero 
et al, 2003). Plants therapeutic activity can be attributed to the presence of secondary 
metabolites. Amongst secondary metabolites known to have shown antiviral activity in 
vitro include tannins, flavonoids, terpenoids, saponins and caffeic acid derivatives (Wyde 
et al, 1993; Namba et al, 1998, Kinjo et al, 2000, Chiang et al, 2002; Ma et al, 2002). 
Previous studies have revealed that Punica granatum had anti-HSV properties (Namba et 
al, 1998). Chemical analysis showed that some medicinal plants such as Agrimonia 
pilosa, Pithecellobium clypearia and Punica granatum had a high content of 
polyphenolics (Li et al, 2004).  Some medicinal plants bearing anti-HSV properties 
attribute their activities to tannins (Chen, 1994; Zhao et al, 2000; El-Toumy et al, 2002).  
Ihlamvu laseAfrika (IHL) is an indigenous medicinal extract that has been 
formulated such that it addresses the deleterious effect of HIV/AIDS and its secondary 
opportunistic infections. Opportunistic infections are regarded as a common complication 
in people living with HIV and AIDS (Jaffe et al, 1983; Selik et al, 1982). It was 
hypothesized that IHL has botanical constituents that have antiviral, antifungal and 
antimycobacterial properties. Moreover, some of its properties include 





In this investigation we aimed at using several polar solvents that would compete 
for relative extraction activity. Studies have shown that the type of solvent used for the 
extraction determines the ultimate compound extracted (Hughes, 2002). The best solvents 
would present with highest threshold (Ct) value. Ct is inversely proportional to viral yield 
(Namvar et al, 2005). The best solvent extract would finally determine MIC.  
 
5.2 Materials and Methods 
5.2.1 Plant extract: IHL was received as a gift donated by the THP, Mr E.B Thabethe. 
The Intellectual Property/Confidentiality Agreement were reviewed and validated by the 
Research Legal Officer and University of KwaZulu-Natal (UKZN) Innovation. The study 
was approved by the ethics committee of the UKZN (ref.  BF069/07). 
 
5.2.2 Preparation of plant extract: Approximately 1kg of a mixture of plant material 
was mixed with about 6L of water and boiled for more than 6 hours.  After cooling, it 
was filtered with muslin cloth and bottled.  A 2L solution of this crude extract of IHL was 
further filtered, freeze-dried and lyophilized. An aqueous medium and solvents (90% v/v) 
of differing polarities were used to extract the product. The solutions were rigorously 
shaken and centrifuged at 3500rpm until the filtrate finally yielded a standard 
concentration of 30mg/mL for each extract.  
 
5.2.3 Acyclovir preparation: Acyclovir (ACV) was purchased from GlaxoSmithKline. 
Stock solution of acyclovir (2mg/mL) was prepared by dissolving the drug in triple 





in solvents to obtain different working solution of 1mg/mL concentration. Diluted stocks 
were used as positive control, deionised water and drug-free solvents were used as 
vehicle controls. 
 
5.2.4 Cells and Viruses: HSV was a donation received from Inkosi Albert Luthuli 
Central Hospital (IALCH). Human epithelial (HeLa) cells were provided by Medical 
Microbiology Department (UKZN). HeLa cells were cultured in minimum essential 
medium eagle (EMEM, LONZA, USA) supplemented with 10% fetal calf serum (FCS, 
Gibco BRL, USA) and 1% L Glutamine and 0.1% streptomycin. During transfections 
cells were grown in 5% FCS without drugs in a 6 well plate. Cell cultures were passaged 
regularly and maintained on 5% FCS without drugs. Cell cultures were incubated in 5% 
CO2 humidified incubator at 37
◦
C.   
 
5.2.5 Viral Inoculation and treatment: HSV2 was propagated on HeLa epithelial cells. 
Virus stock was rapidly thawed and vortexed for 1-2 min. Virus suspension was 
inoculated onto confluent monolayer of HeLa cells at a volume of 500mL of tissue 
culture medium. Cultures were incubated at 37
◦
C in a 5% CO2 incubator overnight. 
Cytopathic effect (CPE) was observed after 1-2 days for HSV2. Cultures were treated 
with IHL 15hours post inoculation as cells started detaching from the surface, taking a 
round shape and lysis as observed under the microscope. Treatment with medicinal 
extracts enabled brief reattachment of cultures however, HSV infected cell lysate had to 






5.2.6 Cultivation of virus for extraction: HSV infected cell lysate was submitted for 
centrifugation. The 6 well plate was gently shaken several times and the supernatant 
including cell cultures were harvested in a sterile centrifuge tube. In order to release 
adenovirus from cells, supernatant with cells was thrice subjected to freeze/thaw cycle 
and centrifuged at 1500 X g for 10 min to pellet the cell debris. The supernatant was 
aliquoted into sterile tubes and stored at -80
◦
C for further analysis.   
 
5.2.7 Viral RNA Extraction with TriZol: The medium was transferred into a 2mL 
eppendorf and 400µL of TriZol was added into 1600µL sample. The sample mixture was 
vortexed for 10 s. Eighty microliter of chloroform was added to each sample and vortex 
for 30 s. The samples were then spun at 12000xg for 15 min @ 4
◦
C to ensure phase 
separation. An aqueous phase containing RNA was transfer into fresh tube and 200µL of 
ice-cold isopropanol was added. All samples were allowed to precipitate at -20
◦
C 
overnight. In order to pellet, RNA was centrifuged at 12000xg for 15 min @ RT. The 
supernatant was decanted and the pellet washed with 200µL of 70% ethanol and then 
centrifuged at 12000 for 10 min at RT. The supernatant was discarded and the RNA 
pellet dried. In order to reconstitute the pellet, 40µL of DNAse-free water was used. This 
was followed by incubation for 10 min for 60
◦
C (in water bath). All RNA samples were 
then stored at -70
◦
C until further use or temporarily put on ice. The quantity of the 
extracted RNA was read on the NanoDrop 1000 Spectrophotometer (Thermo Fischer 






5.2.8 DNAse Treatment: Based on the [RNA] readings, the calculated volume of 10X 
the reaction buffer was added (see appendix). This was followed by addition of equal 
volumes of DNase-1 and RNase free. A 30 min incubation at 37
◦
C was followed by 
addition of 25mM EDTA which was used to stop the reaction and this was followed by a 
10 min incubation at 65
◦
C. The purified RNA was read on NanoDrop in order to verify its 




5.2.9 cDNA synthesis: Reverse transcription was done with first strand High Capacity 
cDNA synthesis Kit by Applied Biosystems. The complementary DNA (cDNA) was 
reverse-transcribed from single strand RNA using random hexamer primers.  Briefly, 
10µL of RNA samples were placed in 96-well reaction plate. Ten microliter of 2XRT 
master mix was put onto each well and was homogenized by pipetting up and down. Plate 
was sealed and then briefly centrifuged to eliminate air bubbles. The plate was then 
loaded onto thermal cycler and cycling conditions set at four step temperature program 
and reaction volume set at 20µL. The DNA quantification was read on NanoDrop Spec 
reader 1000 (Thermo Fischer Scientific, USA) and then stored a -25
°
C until further use.  
 
5.2.10 Real-time PCR Quantification: Quantitative real-time chain reaction (RT-PCR) 
was performed on transcribed cDNA product from HSV-2 treated with several extracts of 
IHL, acyclovir and negative controls. The test was run in triplicate on thermal cycler 
(ABI Prism 7000; Applied Biosystems, Foster City, CA) and each well contained cDNA, 
TaqMan 10X Universal PCR mix (Applied Biosystems) and target-specific TaqMan 





were for the expression of the early HSV-2 gene UL30. Each sample was measured 
quantitatively by RT-PCR and known standards of both HSV-2 were used. Primers used 
for HSV-2:- primers were: - 5’-CTG CCG GAC ACC CAG GGG CG-3’ (forward), 5’-
CGA CCT CCT CGC GCT CGT CC-3’. 
 
The cycling parameter were initial denaturing at 94
°
C for three minutes, followed by 
cycles of denaturing at 94
◦
C for 30 seconds, annealing at 65
◦
C for 30 seconds, extension 
at 72
°
C for 45 seconds and 10 minutes final extension at 72
°
C. The PCR reaction mixture 
contained 0.5µM of each primer, 2.5mM MgCl2, 8% Glycerol, 25µL Mastermix 
(Applied Biosystems, Courtaboeuf, France) and 10µL of cDNA product. Fluorescence 
measurements were recorded at each cycle, which enabled the detection of cycle 
threshold (Ct) value for every DNA sample. The detection threshold was set at 10 copies 
per run. IC50 was defined as the concentration of the antiviral agent that reduced the 
amount of DNA copies by 50% compared to the virus drug-free control (Thi et al, 2006). 
 
5.2.11 Statistical analysis: The Student T-test was used to compare growth inhibition. 
All values were quoted as the mean ± SEM (standard error of the mean) and were 
considered significant at p < 0.05. 
 
5.3 Results  
PCR-based susceptibility: Four out of seven solvents were chosen as the less polar 
solvents namely dichloromethane, cyclohexane and ethyl acetate tended to “burn” the 6-





done with the four most polar solvent extracts and the results were expressed in terms of 




Figure 5.2: The graph display solvents’ extraction potential. 
 An HSV growth inhibitory potential was tested on solvents (burgundy), acyclovir 
extracts (blue) and finally on traditional medicine extracts (green). The extraction 
potential was determined in terms of viral yield, the lesser the viral concentration the 
better the inhibitory potential. However, with regards to the Ct value, the higher the Ct 
value the lesser the viral yield, therefore the best inhibitor. Hence Ct value has an inverse 
relation to viral growth inhibition. In the case of a positive control, the fluconazole in 
EMEM achieved best HSV growth inhibition and fluconazole in ethanol recorded the 
least inhibition. In the case of IHL extracts, IHL in methanol yielded less virus quantity 





least viral quantity as seen with the methanol extract of IHL serves to confirm that HSV 
proliferation was inhibited more than in any other solvent extracts. An IHL extract with 
the least activity was with IHL in acetone (8.50±1.33).  Finally in the case of the four 
vehicle solvents, the one with the best and the least extraction potential, were methanol 
and ethanol respectively.  
 
Minimum Inhibitory Concentration (MIC): Concentrations ranging from 2.00mg/mL 
to 0.1 mg/mL of the methanol extract of IHL were used to determine MIC (IC50). The 

























The Ct value rises as viral load decreases (inverse relation) therefore an increase in 
concentration corresponds to HSV growth inhibition increase, it is a dose dependant 
response. The IC50 of methanol extract is 1.25mg/mL. The trend followed in the graph 
shows an increase from left (0.25mg/mL) to right, the maximum point is reached at 
1mg/mL (Ct = 36.7±0.78), (n=3) followed by a steep decline reaching the lowest (Ct = 
18.9±1.14) at 1.25mg/mL, thus marking our IC50. IC50 can be defined as an antiviral 
concentration that is required to reduce copies of DNA by 50% of the virus drug-free 







PCR-based susceptibility: In this investigation we explored quantitative real-time PCR 
technique as used for quantifying viral concentration taken from supernatants of infected 
and cell cultures that were treated with different solvent extracts of IHL. The procedure 
was comprised of DNA extraction with TriZol and detection using Taqman label probes 
in a 96-well format on an ABI 7000 real-time PCR instrument. The PCR data acquired 
was based on Ct value of each sample that was calculated by determining the point at 
which the fluorescence exceeded background limit of 0.04. Sample preparation in a 
quantitative PCR assay is an extremely cumbersome process that is prone to gross errors. 
During viral lytic cycle, some viruses were released from cells onto supernatant. 
However, some infected cell cultures after treating with test substance tended to adhere 





fact that IHL is concentration-dependent. Nevertheless, the PCR is still regarded as the 
most sensitive and efficient analytical technique.  
 
The efficiency of all solvent extract of IHL were interpreted in terms of viral 
concentration that were expressed as threshold cycles (Ct). The Ct value is described as 
cycle when fluorescence has become detectable and is in exponential phase of 
amplification and the Ct value is inversely proportional to the log concentration of the 
target DNA (Namvar et al, 2005). With the Ct < 20 the corresponding viral copies should 
be above 108 copies/mL (Namvar et al (2005). As a guide standards were set which were 
used for quantitative purposes.  
 
Reoviral infection establishes perturbation in host cell cycle progression. Their actions 
are known to activate cellular transcription factor (Connolly et al, 2000). For the purpose 
of this study, alteration in cell cycle was investigated in relation to gene expression by 
focusing on the UL30 gene. Primers and probes used targeted the DNA polymerase gene 
(UL30) that as mostly targeted by anti-HSV drugs (Greco et al, 2007). 
The Taqman detection tool proved quite sensitive to all cultured specimen since it 
sufficiently identified differences between positive and negative controls as well as 
variations in different concentrations of standards. Based on the results it becomes 
obvious that the negative control should have a low Ct value which is indicative of high 
viral titre (Namvar et al, 2005). The efficiency of drug-free solvents and the respective 
solvent extracts of IHL were denoted by Ct values that ranged between 8 and 18 (figure 





studies concur with our findings. In studies conducted by Espy et al, 2001 and van 
Doornum et al, 2003, the culture-positive samples had Ct values that were below 30 
meanwhile negative-cultures that had also been proved positive by Taqman had their Ct 
values above 30. The MIC’s of this study were determined within a tight margin, the 
medicinal concentration laid between 0.1 mg/mL and 2 mg/mL (figure 5.4). As a result, 
the Ct values for the negative and positive control lay between 35 and 38 respectively. 
The two samples in figure 5.3, the 1.75 and 2.00mg/mL are samples whose viruses were 
not wholly released into the supernatant. Infected viruses experience cytopathic effect 
detach and start floating. The introduction of an antiviral drug tend to reinforce cells 
attachment to the surface whether it is concentration dependant it is unproven, however 
we observed an unease of virus released onto the supernatant with the abovementioned 
concentrations. According to Namvar et al (2005), the viral concentration can be 
estimated based on assumption that the Ct value of 30 corresponds to approximately 
100,000 copies/mL of DNA. In order to confirm a positive culture 20,000 virions are 
required.  
 
Previous works recognizing RT-PCR for HSV analysis with Taqman includes Ryncarz et 
al (1999), whereby they targeted a conserved part of gB and gG for typing. Weidmann et 
al in 2003 used Taqman probes for the identification of different amplicons of HSV-1 
and HSV-2. 
The methanol, ethanol and aqueous extracts of IHL showed antiviral activity although 
methanol extract showed relatively best activity. A study by Nikomtat (2008) revealed 





activities for both methanol and dichloromethane extracts at various stages of HSV 
multiplication cycle i.e. attachment, penetration and multiplication. From that study the 
methanol extract of C. repanda showed highest inhibition.  
 
5.5 Conclusion 
HSV detection and quantification with Taqman after extraction with TriZol is quite 
sensitive and it has proven most susceptible to methanol-based extract of IHL which 
displayed anti-HSV properties. Caution should be taken however during harvesting of the 
infected lysate that all viral particles are released into the supernatant especially when 
viral quantification is incumbent. The active principle extracted with the methanol 
warrants further investigation into its chemical profile. Nonetheless, IHL has proven to 
have antiviral properties. 
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6.0 Abstract 
Traditional medicines are anecdotally claimed to have positive effects on human 
immunodeficiency virus or Acquired Immunodeficiency syndrome (HIV/AIDS) patients 
though there has not been scientific validation of such claims. They could either act 
directly against the HIV or indirectly by inhibition of organisms causing opportunistic 
infections.  To investigate antifungal properties of a traditional medicine, Ihlamvu 
laseAfrika (IHL), used for treatment of AIDS related infections. A crude extract of IHL 
was lyophilised and reconstituted into stock standards that were prepared using seven 
solvents of differing polarities. The disk diffusion technique was used to assess growth 
inhibition of these extracts against Candida albicans and Cryptococcus neoformans. 
Using the extract displaying the greatest activity, several working matrix-equivalent 
concentrations made were used to determine minimum inhibitory concentration (MIC). 
Confirmatory test of MIC‟s was done with broth microdilution method. The minimum 
lethal concentration (MLC) was the subsequent test conducted after broth microdilution. 
Results: C. albicans displayed extreme susceptibility towards an aqueous extract of IHL 
(30 mg/mL) than C. neoformans (p <0.001). The corresponding zone of inhibition for C. 






culture. Both organisms had MIC‟s of 1mg/mL.  The MIC‟s recorded for both C. 
Albicans and C. neoformans with broth microdilution technique was 2mg/mL,   The 
MLC‟s recorded against C. albicans and C. neoformans were 32.0 and 8.00 mg/mL 
respectively. IHL proved fungicidal at higher concentrations and fungistatic at low 
concentrations. 
Conclusion: IHL displayed antifungal activity and the broth microdilution method 
proved to be a sensitive tool for growth detection. 
 
Keywords: IHL, Cryptococcus neoformans, Candida Albicans, broth microdilution 
 
6.1 Introduction 
Opportunistic fungal infections account for 58% to 81% prevalence and 10% to 20% 
morbidity and mortality rate (Drouhent et al, 1989) especially in immunocompromised 
hosts including organ transplant patients (Fischer-Hoch et al, 1995).  Candidiasis is an 
example of nosocomial infections as a result of organ transplant (Cox et al, 1993; 
Holmstrup et al, 1990, Odds, 1988). Current antifungal treatment options are lacking in 
efficacy whilst showing high level of toxicity. Drug resistance has been greatly enhanced 
with AIDS epidemic highlighting the need to develop new classes of antifungal drugs 
(Sheehan et al, 1999). Both Candida albicans and Cryptococcus neoformans have 
recently displayed azole-resistant associated with AIDS epidemic (Poeta et al, 1998). 
 
Antibiotics were discovered in 1940 as synthesized drugs either by man or 
microorganisms that act to inhibit growth of other microorganisms or kill them (Ritter et 






treating fungal infection. Its efficacy however has been thwarted by its serious side 
effects that may be life-threatening including nephrotoxicity, chills and fever. 
Fluconazole and itraconazole are also two useful antifungal treatment drugs classified as 
azole (Graybill, 1989). It is such limitations that bring about the need for new antifungal 
agents (Salama et al, 2001). 
 
Infectious diseases have been treated with plant extracts in Africa for centuries. Sexually 
transmitted diseases (STD) always responded well to such treatments. In 1999 there was 
an estimated 340 million new cases of STD reported (WHO, 2001). The prevalence of 
STD has been rife in South and East Asia followed by sub-Saharan Africa, Latin 
America, and the Caribbean (WHO, 2001). The organisms would prefer warm, moist and 
dark places such as the mouth, genitals and anus.  The infecting organisms would vary 
from bacteria, viruses and fungi. There is growing evidence that prove that these 
pathogens facilitate acquisition and AIDS transmission (Wasserheit, 1992; Fleming et al, 
1999). It is believed and thus proven that STD regulation may greatly control HIV 
infections (Grosskurt et al, 1995; Gilson et al, 1997; Mayaud et al, 1997). 
 
IHL is the traditional medicine that is currently anecdotally used by people living with 
AIDS (PLWA). It is a polyherbal remedy consisting, among others, Terminalia L spp 
which has been investigated for antifungal activity (Baba-Moussa et al, 1999; Silva et al, 
1996).   According to Baba-Moussa et al in a study conducted in 1999, its antifungal 






(2005), on antifungal properties of Combretaceae, it displayed an MIC as low as 
0.02mg/mL. 
In this study, the disk diffusion method was used to determine both pathogens‟ 
susceptibility towards IHL and also establish MICs. The disk diffusion method had 
previously been used to determine antimicrobial activity (Salie et al, 1996; van Staden, 
1997; Kelmason et al, 2000; McGaw et al, 2000; Madomombe et al, 2003; Samie et al, 
2005). Further confirmatory test with the broth microdilution technique would also 
determine species susceptibility as well as its MIC. Broth microdilution has proved useful 
for antimicrobial screening (Espinell-Ingroff et al, 1995). As a spectroscopic technique, 
broth microdilution best mimics dynamics of fungus in a biological fluid (Thamburan et 
al, 2006). 
 
6.2 Materials and Methods 
6.2.1 Plant extract. The traditional medicine, IHL, was obtained from Mr E.B Thabethe, 
a local traditional health practitioner (THP). The materials transfer agreement was 
reviewed and validated by the Research Legal Officer and the University of KwaZulu-
Natal (UKZN) Innovation. The study received ethical approval from the UKZN ethics 
committee (ref. BF069/07). 
 
6.2.2 Preparation of plant extracts. Approximately 1kg of a mixture of herbs was 
mixed with about 6L of water and boiled for more than 6 hours.  After cooling, it was 
filtered with muslin cloth and bottled.  A 2L solution of this crude extract of IHL was 






ethanol (EtOH), acetone, ethyl acetate (EA), cyclohexane, dichloromethane (DCM) and 
water were used to extract the product. The solutions were rigorously shaken and 
centrifuged at 3500rpm until the filtrate finally yielded a standard concentration of 
30mg/mL for each extract.  
 
6.2.3 Micro-organisms. An isolate of C. albicans was obtained from Inkosi Albert 
Luthuli Central Hospital (IALCH) and C.  neoformans was obtained from the Medical 
Microbiology Department, UKZN. The C. neoformans isolates were suspended in water 
and kept at ambient temperature until further use. 
 
6.2.4 Antimicrobial susceptibility testing. The disk diffusion method was performed 
according to M44-P specifications. Overnight broth cultures were adjusted to match 1 
and 0.5 McFarland standards for C. neoformans and C. albicans respectively. Molten 
Sabourad Dextrose Agar (SDA) was allowed to cool to 45
◦
C. This was transferred into 
sterile Petri dishes and allowed to solidify. Three drops of the inoculum were put on 
plate‟s surface and these were streaked with sterile loop to ensure uniform growth of 
cultures. Susceptibility was carried out with 30mg/mL concentration of the six extracts 
per organism. Three disks were delivered onto each plate‟s surface and tests were done in 
triplicates. Disks impregnated with drug-free solvents were assayed along as negative 
controls and fluconazole (2mg/mL) (Hexal Pharma) served as positive control. Plates 
were incubated at 37
◦
C for 24 and 48 hours for C. albicans and C. neoformans 






millimeters. The defining criteria would be the measure of the zones diameter hence 
solvent extract displaying best activity would have largest zones of inhibition. 
 
6.2.5 Minimum Inhibitory Concentration (MIC) 
6.2.5.1. Disk Diffusion: The medicinal extract displaying largest zones of inhibition from 
the aforementioned test was used to determine MIC. That extract was serially diluted 
from 60mg/mL to 0.01mg/mL concentrations. Fluconazole was used as positive control 
and drug-free solvent served as a negative control. A loopful of fungal organisms 
previously diluted was used to inoculate each plate. These plates were incubated at 35
◦
C 
for 24 and 48 hours for C. albicans and C. neoformans respectively. Zones of inhibition 
were recorded in millimeters. The MIC of an extract was defined as the lowest 
concentration that would not permit growth of test organisms. 
 
6.2.5.2. Broth Microdilution: To mimic fungus dynamics within bodily fluids, MIC in 
broth was determined (Thamburan et al, 2006). Minimum inhibitory concentration was 
performed with broth microdilution assay as defined in NCCLS guidelines document 
M27-A12 however, with slight adjustments. In brief, RPMI 1640 (Sigma) was 
supplemented with 0.3g of glutamine/L buffered with 0.165M 
morpholinepropanesulfonic acid (MOPS, Gibco Laboratories) and its pH was adjusted to 
7.0 and 2g of glucose was added. One hundred microliters of fluconazole and drug-free 
medium (controls) and serially diluted traditional medicine were dispensed into a 96 well 
microtitre plate (Falcon 3072; Becton Dickson). The concentration of traditional 






inocula (100µL) were adjusted spectrophotometrically. Briefly, an inoculum was 
prepared from each isolate taken from 24 hours old culture grown at 35
◦
C and the 
turbidities of the resulting yeast suspension were adjusted spectrophotometrically from 1 
X10
6
 to 5 X 10
6
 at 530nm. The adjustments were done such that C. Albicans had a 
percent transmission matching 0.5 McFarland and C. neoformans matched 1 McFarland. 
Plates were incubated for 24 to 48 hours for both species respectively. The drug-free and 
yeast-free controls were also added. Plates were briefly shaken at 250rpm at ambient 
temperature and absorbance read with microplate reader (Perkin Elmer) at 630nm 
followed by incubation for 24 and 48 hrs, C. albicans and C. neoformans respectively. 
After incubation, the species proliferation was reassessed spectrophotometrically and the 
second absorbance readings recorded. Hence, proliferation was determined by subtracting 
the absorbance values acquired before and after incubation (Das et al, 2010). The MIC 
was determined with reference to density of drug-free control and it was defined as the 
lowest antifungal concentration required to inhibit 50% or 80% of the control growth 
(Lozano-Chiu et al, 1999; Nguyen and Yu, 1999; Odds et al, 1995; Pfaller et al, 1995).  
 
6.2.5.3 Minimum Lethal Concentration (MLC): The advantage with broth 
microdilution assay is its ability to further determine fungicidal/fungistatic activity. The 
minimum lethal concentration of each dilution was determined by plating 100µL extract 
sample displaying no observable growth onto SDA. According to definition, MLC is the 
lowest concentration of the drug at which no colonies displayed visible growth, hence at 







6.2.5.4 Statistical analyses: The Student T-test was used to compare zones of inhibition. 
All values were quoted as the mean ± SEM (standard error of the mean) and were 
considered significant at p < 0.05 
 
6.3 Results  
Figure 6.1 shows results of antifungal activities of seven solvents of differing polarities 
used to extract antifungal compounds from IHL, and tested against C. neoformans using 
the disk diffusion assay compared with fluconazole as a positive control.   In the case of 
fluconazole, triple distilled H2O (tdH2O) was the best solvent to yielding a zone of 
inhibition of about (39.7±0.94) mm, followed by ethanol (29.7±3.68) mm, and the least 
was cyclohexane which results in no inhibition.  All the solvents used to extract IHL 
resulted in an inhibition zone of less than 10mm, with the exception of tdH2O with 
(21.1±2.40) mm.  Acetone, dichloromethane and ethanol resulted in equivalent zones of 
inhibition of C. neoformans making them not suitable solvents to use.  Furthermore, the 
zones of inhibition by IHL extracted with these solvents may not reflect its efficacy 
against C. neoformans but rather that of the solvents.  On the one hand, tdH2O, methanol, 
ethyl acetate and cyclohexane supported antifungal activities of IHL.  However, tdH2O 





































Figure 6.1: Results of antifungal screening of extracts of IHL against Cryptococcus 
neoformans using the disk diffusion assay and fluconazole as the positive control. Tests 
were done fifteen times for statistical purposes. 
 
The seven extracts of IHL traditional medicine extracts were also tested against C. 
albicans as indicated in figure 6.2 using fluconazole as a positive control.  The results 
were similar to those of C. neorformans in that, triple distilled H2O (tdH2O) was the best 
solvent to use with fluconazole yielding a zone of inhibition of about (30.67±0.57) mm, 
followed by ethanol (26.0±1.00) mm, and the least was cyclohexane which resulted in no 
inhibition.  All the solvents used to extract IHL resulted in an inhibition zone of less than 
10mm, with the exception of cyclohexane and ethanol where IHL was not efficacious 



































Figure 6.2: Results of antifungal screening of several extracts of IHL tested against 
Candida albicans with disk diffusion assay are displayed. Fluconazole was used as a 
positive control and tests were also done in replicates of fifteen. In the case of 
fluconazole extracts, it displayed largest zones of inhibition than most IHL extracts and 
controls alike. In this instance the positive control with the largest zone (32.0±1.00) mm 
was achieved with ethyl acetate (E.A) followed by an aqueous extract (30.7±0.58) mm 
and the least was the cyclohexane extract (8.67±1.15) mm. The two negative controls, 
cyclohexane (9.67±1.53) mm and ethanol (9.67±1.53) mm displayed antimicrobial 
properties with similar inhibitory potential making their contributions towards growth 
inhibition impossible to ignore (p<0.05). Finally, amongst IHL extracts, it was noticed 
that an aqueous extract displayed the largest zones of inhibition (10.5±1.64) mm and the 







Having established the aqueous extract as the most active, it was therefore used to 
determine MIC of IHL for both organisms.  The disk diffusion results in figure 6.3 depict 










Figure 6.3: The dose dependant response curve of C. neoformans and C. albicans after 
treating with an aqueous extracts of IHL in which the MICs were concluded using the 
disk diffusion assay.  Fluconazole was used as a positive indicator and tests were also 
carried out in replicates of fifteen in each organism. C. neoformans proved to be the most 
susceptible towards IHL against C. albicans. However, both organisms achieved similar 
MIC at 1mg/ml however, C. neoformans had the largest zones of inhibition (11.4±0.55) 
mm confirming its sensibility whereas (10.6±1.34) mm for C. albicans was produced (*- 
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Figure 6.4: The above graph displays MIC results obtained with broth microdilution 
method. In this graph an apparent proliferation decrease in both C. neoformans and C. 
albicans that is dose-dependant was depicted. Both C. albicans and C. neoformans shared 
a common MIC at 2mg/mL. The corresponding percentage growth at 2mg/mL was 
(36.7±2.924)% and tests were done in triplicates. 
 
The broth microdilution test gave way to the determination of the minimum lethal 
concentration (MLC) of the neat extract of IHL which helped ascertain the extract‟s 











Table 6.1: In the above table the MLC results of both C. albicans and C. neoformans 
against neat extract of IHL are illustrated. Y represented a “yes” and N represented a “no” 
to growth. The MLC of IHL acquired when tested against C. albicans and C. neoformans 


















Disk Diffusion: IHL is hypothesized to act as a non-specific repressor of pathogens a 
person living with HIV and AIDS presents with. The antifungal properties of IHL has 
been confirmed thus further justifies its utilization by people living with AIDS (PLWA) 
who present with opportunistic infections due to C. albicans and C. neoformans, 
depending on severity of damage to the immune system.  
 
The agar disk diffusion method has gained a wide appreciation and reputed for best 






et al, 2006) and most particularly, antifungal properties. The agar disk technique has 
proven most appropriate for preliminary screening of trace substances or small sample 
(Rios et al, 1988). It was also established that antifungal properties of IHL varies with 
solvent utilized. Previous studies also concur with the notion that in order to extract 
biological active principle from plant material, the choice of solvent used for extraction 
plays a crucial (Parekh et al, 2005). Water represents a universal solvent that can extract 
active compounds having antimicrobial properties that most THP‟s use. Complementary 
to the work done by THP‟s, research into medicinal plants have revealed even the most 
effective means of extraction involving solvents (Parekh et al, 2005).   The choice of 
solvent utilized should be such that it should not partake in the bioassay (Ncube et al, 
2007). An aqueous control displayed no growth inhibition hence, the result output was 
zero. However, solvents such as acetone*, dichloromethane*** cyclohexane and ethanol* 
with growth inhibition recordings that are above 5mm, they play a significant role (*- 
significant, p<0.05, ***- extremely significant, p<0.001 respectively) to be ignored.  
 
Ethanol, isopropyl and propanol proved to possess broad-spectrum antimicrobial 
activities against vegetative bacteria, viruses and non-sporicidal fungi (Morton, 1983). 
The results due to an ethanol extract of IHL seem to concur with the said statement. For 
instance in figure 6.1, there is significant and obvious contributions attributed to ethanol, 
DCM, acetone and cyclohexane controls. It has also been established that IHL possess 
antimicrobial properties hence, it is incumbent that potentiation or synergism of 
antimicrobial properties should be anticipated. However, the ethanol extract output seems 






ethanol extract results might be as a result of  denaturation of certain proteins (Larson et 
al, 1991, Morton, 1983) thus lessening antimicrobial effect of IHL as it was observed 
during plant extraction which resulted in the formation of two layers.  
 
In a study done by Thamburan et al (2006), the susceptibility of C. albicans, Candida 
glabrata, Candida Krusei and C. neoformans towards Tulbaghia alliacae, Allium sativum 
and Tulbaghia violacea that was extracted with an aqueous, methanol and chloroform 
solvents on an agar plate method was established. From the study it was concluded that 
the chloroform extract of T. alliacea was the most potent than A sativum and A violacea 
in inhibiting growth of C. albicans. It therefore seems that C. albicans proved most 
sensitive to test substances than most organisms. According to the THP, IHL is composed 
of several plants. The active components whether working singularly or in unison in 
inhibiting fungal growth, only the fractionated components could confirm, however the 
results seemed to have displayed synergism as observed with both strains in which C. 
albicans proved most sensitive (figure 6.3).  
 
Broth microdilution:  The microtitre plate or broth microdilution technique has proven 
most useful in determining MIC in large scales. The presentation of IHL posed a serious 
challenge especially when proliferation had to be visually assessed. In general, species 
proliferation after incubation has been assessed with changes in turbidity, a marker of 
species growth. The wells that seem clear would denote an MIC of an agent (Das et al, 
2010). However, some researchers chose indicators such as tetrazolium salts or resazurin 






(Devienne et al, 2002; Matsumoto et al, 2001). Spectrophotometric assessment was 
chosen because IHL presented as a dark and viscous substance which upon serially 
dilutions introduced colour variance thus giving „phenotypic‟ inconsistencies. 
Subsequently, to determine organisms‟ proliferation the absorbance values were 
subtracted from those acquired before incubation. That was done to eliminate the 
interference of the test substance (Das et al, 2010). MIC‟s were thus 
spectrophotometrically determined by comparing against density of the drug-free control 
since MIC‟s is defined as the lowest antifungal concentration that inhibit 50 or 80% of 
the drug-free control (Lozano-Chiu et al, 1999; Nguyen and Yu, 1999; Odds et al, 1995; 
Pfaller et al, 1995). 
 
It was incumbent that the negative control displayed 100% proliferation of species with 
broth technique in order to enable distinguish the activity of the test substance. IHL 
markedly decreased species proliferation in a dose dependant manner. A sharp decline 
that resulted in 80% growth inhibition of C. albicans when compared to the negative 
control, befitting definition of an MIC was observed.  
 
Susceptibility testing using broth microdilution method proved quite sensitive and 
reproducible as well reputed as best tool since the test displayed good correlation in vitro-
in vivo clinical findings in oropharyngeal candidiasis patients infected with HIV 
(Revankar et al, 1998). The MIC‟s established with both broth microdilution (2mg/mL) 
and agar plate disk assay (1mg/mL) on C. albicans showed slight difference. The study 






is the most sensitive. However, according to Revankar et al (1998) in a similar study they 
felt that such deduction was most unlikely and they subsequently dubbed their results as 
inconclusive. 
 
Minimum lethal concentration: The advantage of performing broth microdilution assay 
is that it gives way to the agar dilution method which helps determine agent‟s lethal 
activity. The minimum lethal concentration (MLC) of IHL was determined on SDA 
plates.  The MLC can be defined as an antifungal concentration of an agent at which no 
colonies displayed visible growth after 24hrs and 48hrs incubations of C. albicans and C. 
neoformans respectively. The MLC assay was performed by aliquoting 100µL of each 
sample and plated that onto agar followed by species incubation. Normally samples 
would be taken where no growth displayed on microtitre plate. The results as seen in 
table 6.1 proved C. neoformans to be the most sensitive of the two organisms. Apparently 
with the two disks assays (MIC and MLC), a trend was noticed whereby C. neoformans 
again proved relatively sensitive towards IHL. C. neoformans and C. albicans were both 
killed at 8mg/mL and 32mg/mL respectively. Resilience displayed by C. albicans lead to 
an observation that it doesn‟t readily respond to medication be it orthodox drugs or 
traditional medicines as witnessed in both figures 6.1 and 6.2 (aqueous extracts). 
 
When comparing the effect of IHL against T. alliacae, in a study by Thamburan et al 
(2006) it was shown that T. alliacae extract was capable of reducing cell densities 
(colony forming units) 5 hours post-treatment and an additional 1000 fold reduction after 






activity towards C. albicans and C. neoformans at 32 mg/mL and 8mg/mL, respectively. 
Both fungicidal concentrations (8mg/mL and 32mg/mL) as sampled on the microtitre 
plate fall below the percentage growth rate (20%) (figure 6.4) which confers fungicidal 
characteristics to IHL. Furthermore the agar disk diffusion MIC‟s should thus be also 
considered to be fungistatic as well since these concentrations rather inhibit proliferation 
as opposed to killing these pathogens. It can be argued that the MLC of IHL could not 
have been realized had only concentrations displaying no growth were considered. Such a 
hypothesis is viewed to be limited to test substances that introduce no colour changes 
upon utilization. The MLC exercise had previously been limited to concentration that 
prohibited growth (Falahati et al, 2006). However, in this investigation what became 




IHL displayed positive activity with regards to growth inhibition towards C. neoformans 
and C. albicans, they both proved susceptible towards it. Further fractionation and 
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An investigation into 

















Introduction: Ihlamvu laseAfrika (IHL) is traditional medicine (TM) that is currently 
used for human immunodeficiency virus (HIV) and Acquired Immunodeficiency 
Syndrome (AIDS) related infections in KwaZulu-Natal. Several properties characterize 
IHL since immunocompetent and patients co-infected with Mycobacterium tuberculosis 
draw benefit. Research revealed immense antimycobacterial properties Euclea natalensis 
plant species had displayed irrespective of portions of the plant used (Lall et al, 2000). 
These may singularly or together with other plants species constituting IHL treat 
tuberculosis.   
Objective: To investigate antimycobacterial properties of IHL used for control tubercular 
infection. 
Materials and Methods: A crude extract of IHL was prepared as previously stated. 1% 
proportion method and the agar dilution technique were used to measured growth 
inhibition of H37Rv against several extracts of IHL. The plant extract capable of 
displaying the strongest activity was used to determine MIC.  
Results: H37RV strain proved susceptible towards IHL since visible growth less than 1% 
of the control was observed. Similarly, the agar dilution results concurred with 1% 
proportion results. The acetone extract of IHL displayed best activity, the MIC of 
16mg/mL was common in both methods. 
Conclusion: The acetone extract of IHL displayed antimycobacterial properties despite 













The Southern African region is enriched with a wide array of plant species (Arnold and 
de Wit, 1993). A multitude of these plants-bearing-health-benefits have been utilized for 
centuries by indigenous people (Watt and Breyer-Brandwijk, 1962; Iwu, 1993; Hutchings 
et al, 1996; Eldeen et al, 2005). It is only after lab-based research ensued that diseases 
treated with medicinal plants were identified and classified according to their symptoms. 
For instance, investigation into the following plant species viz:- Acacia nilotica, Cassine 
papillosa, Chenopodium ambrosioides, Combretum molle, Croton sylaticus, Cryptocarya 
latifolia, Ekebergia capensis, Protasasparagus africanus, Rapanea melanophloeos etc, 
used to treat symptoms such as coughs, fever and blood in sputum of which these 
symptoms were later identified as classic Tb-related symptoms (Watt et al, 1932, Pujol, 
1990; Hutchings, 1996). 
 
Several health benefits may be found in one plant species however, these active 
compounds can be evenly spread throughout. In the Eastern Cape (South Africa), 
Pelargonium reniforme Curtis is one indigenous multipurpose plant that is a classical 
example (Latte et al, 2004). Investigation into P. reniforme aerial part displayed presence 
of benzoic, cinnamic acid derivatives, flavonoids and tannins as its phenolic content.  
Tannins play an active role in wound healing (Kolodziej, 2007). Tannins have been also 
been featured by most healers in their regimen used to treat gastrointestinal disorders for 
example, diarrhea. The root infusion of P. reniforme in Southern Africa features quite 
prominently because of its curative and palliative effects in respiratory tract infections, 







Brandwijk, 1962; Hutchings 1996). Also found in the root portion also are 
proanthacyanidins that are included in the treatment of several ailments (Scholz, 1994; 
Hor et al, 1995). Furthermore in the root are phenolic compounds, phenolics have 
scavenging effect on hepatic disorders (Latte and Kolodziej, 2004; Kolodziej, 2007). 
Phenolic compounds as well as coumarins have moderate antibacterial effect and strong 
immunomodulatory effects (Kayser and Kolodziej, 1997). Other studies revealed its 
antibacterial, antifungal and antitubercular properties based on the root part which 
explains its utilization in tuberculosis (TB) and coughs treatment (Mativandlela et al, 
2006). 
 
It has been reported elsewhere that traditional medicine usage is widespread. In Rwanda, 
mycobacterium showed susceptibility towards Tetradenia riparia and Bidens pilosa, in 
vitro. When the active ingredient was isolated, it inhibited Mycobacterium tuberculosis 
(MTB) growth at 100mg/mL (van Puyvelde et al, 1994). In China, a traditional drug 
known as A-ji-ba-mo used for MTB treatment is derived from the root of Dipsacus 
asperiodes (Zhou et al, 1994). 
 
The properties of an MTB bacillus may include anaerobic, non-motile bacillus with an 
estimated 21 to 28 days growth period in vitro as well as in vivo. It is characterized by its 
thick waxy cell wall that enables it survival within harsh conditions including toxic 
conditions with macrophages (Bowler and Chou, 2004; Weatherrall et al, 1988). Its 
ability to lie dormant makes it hard to eradicate, hence it latent effect especially amongst 







Reliance on traditional medicine is inevitable since it spans long history of use and the 
emergence of resistant strains further justifies its use. 
 
Effective TB treatment is required however not only due to co-infection in the case of 
AIDS patients however just so that TB is effectively controlled as a health concern 
affecting immunocompromised and immunocompetent alike (WHO: IUATLD Working 
Group, 1989).  
 
The emergence of drug resistance calls for development and search for new therapeutic 
agent that effectively control MTB infection (Suksamram et al, 2003; Lee et al, 2006; 
Jimenez-Arellanes et al, 2007). Treating drug-resistance TB is difficult and very 
expensive. Worst TB treatment would require surgery to remove some infected portion of 
the lung drugs couldn’t access (National Jewish Medical and Research Centre, 1994). For 
some case treated in the USA and other resourceful region, the cost attached to drug-
resistance can amount to US$ 250 000 per case involving a long course of rather toxic 
drugs (WHO, 1997). 
 
Currently South Africa is faced with massive multi-drug resistance and extreme-drug 
resistance case of TB (Gandhi et al, 2006). Antimicrobials taken from natural sources 
according to research have huge impact on human health as it has been observed in 
undeveloped countries. These interventions have been greatly improved in developed 
countries as a result a number of drugs have been synthesized and developed from natural 







7.2 Aim of the study 
1. To investigate antimycobacterial activity of extracts of IHL, in vitro.  
2. To validate results obtained with 1% proportion versus agar dilution’s regarding 
activity of the choice of solvent. 
3. To determine MIC with best extracting solvent. 
 
7.3 Materials and Methods 
7.3.0 Chemicals and Reagents 
7.3.1 Chemicals 
All chemicals (acetone, methanol, ethanol, ethyl acetate, hexane and dichloromethane) 
were of AR grade and were all purchased from Sigma Aldrich Company. Isoniazid (INH) 
and rifampicin (RIF) were purchased from Sigma Aldrich Company. 
 
7.3.2 Microorganisms 
The H37Rv strain was donated by the Medical Microbiology department, TB laboratory. 
The mycobacterium tuberculosis strain was cultured in Middlebrook 7H10 supplemented 
with casitone and (oleic acid + albumen + dextrose + catalase) (OADC). 
 
7.3.3 Anti-MTB drugs 
Two anti-MTB drugs of masses 0.1605g of INH and 0.100g of RIF were extracted with 
20mL of each of the six solvents and distilled water. They constituted a positive control 








7.3.4 Plant Extraction 
IHL (coutersy of E.B Thabethe) was assessed for its antimycobacterial properties. 
Approximately 9.00mg of lyophilized medicinal product was dissolved in 300mL 
deionized water and extracted with both aqueous and solvent media. 
 
7.3.5 Plates Preparation 
For susceptibility testing Middlebrook 7H10 (Difco, Becton, Dickson & Company, 
Sparks, USA) agar was used to prepare plates. Approximately 7.6 g of 7H10 agar base, 
2mL of glycerol, 0.4 g of casitone and 360 mL of deionised water were homogenously 
mixed in 500mL Schott bottles. The mixture was autoclaved at 121
◦
C for 15 min and 
allowed to cool to 52-56
◦
C. Forty milliliters of OADC was added followed by further 
addition of controls and 10mg/mL of the seven different medicinal extracts at a ratio of 
(1: 4 v/v, plant extract: culture medium). Quadrant plates to be used for susceptibility 
testing were configured such that there was drug-free quadrant and quadrants 2, 3 and 4 
contained 5mL of INH, RIF and traditional medicine respectively.  
 
7.3.6 Susceptibility testing  
An H37Rv suspension was prepared and adjusted into liquid suspension that matches 1 
McFarland standard. One McFarland made from H37Rv suspension was reported to be 
equivalent to 1mg/mL (Kent at al, 1985). The suspension was diluted ten-fold and was 
streaked onto plate’s surface with and without plant extracts in order to determine colony 
forming units. After 21 days incubation, CFU were determined with the aid of Quebec 







counts on extracts containing quadrant versus extract-free quadrant. The second 
determinant was the solvent extractant displaying relatively best colony inhibitory 
activity. 
 
7.3.7 Minimum Inhibitory Concentration (MIC) 
One thousand milligrams of lyophilized product was made up into 100mL of distilled 
water. This was shaken and centrifuged at 3500rpm. The filtrate was used to constitute a 
stock. From the stock, several working matrix-equivalent concentrations were made and 
used for MIC exercise. Plates were prepared in similar fashion to susceptibility assay 
except that various concentrations were incorporated onto each of the plates. A plant 
extract exhibiting strong CFU inhibitory activity was used to determine MIC and the 
concentrations used ranged from 25mg/mL to 2.5µg/mL. Quadrants displaying 1% 
growth or more to growth in the control were considered resistant to that concentration. 
The MIC was regarded as that concentration that inhibited 100% colony growth. 
 
 
7.3.8 MIC (Agar Dilution method) 
Several concentrations of the test substance were serially diluted to match concentration 
ranges of 0 to 64 mg/mL and these were incorporated onto agar and left to dry. The 
dilutions made such that the concentration was made in 10mL of the medium and 5mL of 
the medium at each concentration was then poured into quadrant corresponding to 







The standard inoculum size matching 1 McFarland standard were inoculated onto plate 
surfaces and incubated for 21 days. After incubation the effect of the tests substance was 
measured in terms of growth inhibition. The MIC was defined as the lowest concentration 
of the extract inhibiting visible growth of each microorganism on the agar plate (Nostro 
et al, 2000; Hammer et al, 1999). Alternately, the number of colonies in drug containing 
quadrant were counted and compared to those in drug-free quadrants and expressed in 
percentages. 
 
7.4 Results  
Isolates are considered resistant if colonies grown in drug presence are greater or equal to 
1% of colonies growing in drug-free control quadrant. The results of an aqueous extract 
(113%) as depicted in figure 7.0, the number of colonies counted in drug containing 
quadrant was well above 50 counts which far exceeded 1% of colony growth in drug-free 
control, thus proving existence of resistant.  
 
The second set in graph represent ethyl acetate solvent (negative control), rifampicin 
solvent extract (positive control) and a medicinal ethyl acetate extract, the test substance. 
From this set of results, it becomes clear that the H37Rv displays resistance towards IHL, 
since growth of 5% was observed.  
 
The third set of results as depicted in the bar graph shows acetone solvent (negative 
control), the acetone extract (positive control) and the traditional medicine extract (test 







clear that acetone extract had the greatest inhibitory activity. This is so because colonies 
counted on the acetone extract quadrant were 0.2% less than colonies counted on the 
control quadrant, essentially rendering acetone extract when compared to ethyl acetate 
extract (5%), the best. The methanol extract results also proved resistance (50%). In the 
case of DCM extracts (100%), resistance was again experienced and the positive control 
displayed alarming H37Rv growth. Ethanol extracts (110%) also displayed strong 
resistance since growth experienced in all quadrants could not fulfill the definition of the 


























Figure 7.0: The effect of different IHL solvents’ extracts on Mycobacterium tuberculosis 
growth inhibition using 1% proportion method (n=9).  
The concentration of IHL remained at 30mg/mL for comparative reasons. [MeOH= 
methanol; E.A= ethyl acetate; Acet= acetone; DCM= dichloromethane; EtOH= ethanol; 







solvent]. All negative controls are depicted in blue, the positive control are coloured in 
burgundy and all IHL extracts are given in white.  
 
Table 7.0: The effect of solvent type used to extract IHL using an agar dilution method. 
 
MIC H37Rv (30mg/mL) 
________________________________________________________________________ 
DCM  Acet  MeOH  EtOH  E.A     H2O 
-ve contrl *  R  R  S  *      R 
+ve contrl *  S  R  S  *      S 
T/M  *  S  R  S  *      R 
 
 (-ve contrl = negative control of a given solvent used, +ve contrl = fluconazole used as a 
positive control, T/M = traditional medicine extract and * denotes no results as plates 
were damaged by the solvent, R = resistant and S = susceptible. Above are results of an 
agar dilution assay. Similarly, the IHL concentration remained at 30mg/mL for 
comparative reasons, (n=3). 
 
Solvents such as dichloromethane and ethyl acetate and their relative IHL extracts and 
RIF extracts when brought onto a plate surface they virtually destroyed the plate, hence 
the results were declared null and void. The H37Rv strain once more proved to be 
susceptible towards all acetone extracts (table 7.0), no growth was observed with IHL 
extract in as much as it was observed in the negative control. In the case of all methanol 
extracts, the MTB strain proved resistant towards methanol extract of IHL and its positive 







observed with IHL extract as well as in its positive control. In the case of ethyl acetate, 
the results were also declared null and void, all plates reacted with the solvent. Finally, an 
aqueous extract, recorded an alarming growth in both IHL extract and the negative 
control. From the above findings, it was concluded that the acetone-based extract of IHL 
achieved the best MTB growth inhibitory activity than other solvent-based extracts. The 
growth inhibition activity of  the acetone extract of IHL when agar dilution method was 
used to determine MIC, proved that MTB could not grow at MIC of 32 mg/mL (table 
7.1).   
 
Table 7.1: MIC results for an acetone-based extract of IHL using Agar dilution method. 
 
MIC Medicinal Concentration (acetone extracts)  MTB Growth (Y/N) 
64 mg/mL       S 
32 mg/mL       S 
16 mg/mL       R 
8 mg/mL       R 
4 mg/mL       R 
2 mg/mL       R 
1 mg/mL       R 
0 mg/mL (neg control)      R 
RIF (pos control)      N 
 
(*R represents resistant strains which therefore means there was positive growth and *S 
means susceptible strains therefore no growth observed). The results were done in 








The susceptibility test performed on Mycobacterium tuberculosis H37Rv was done 
according to a 1% proportion method in which the search for best extracting solvent was 
also carried out. The results as depicted in figure 7.1 portrayed acetone-based extract of 
IHL as the one with relatively best growth inhibitory activity. The set of results displayed 
in tables 7.2 and 7.3, seek to establish why acetone-based extract of IHL and its negative 
control both qualify the definition of a 1% proportion method. The vehicle control 
showed colony counts in excess of 200 whereas no growth was observed in a quadrant 
bearing acetone extract. In a study done by Manjunathan et al (2010) on solvent based 
effectiveness of antibacterial activity of edible mushroom Lentinus tuberregium, it was 
observed that the antibacterial activity of a mushroom sample varied according to solvent 
used. According to Moore et al, (1999) an isolate is considered susceptible to an anti-
MTB agent if the number of colonies counted in the presence of a drug are less than 1% 
of the colonies grown in drug-free control quadrant. 
 
Table 7.2 (left) and 7.3 (right) displays rounded off figures of results for an acetone-









+ve control -ve 
control 
Acetone INH Rif Acetone 
<20 <20 <20 2+ 
 <20 <20 <20 3+ 
<20 <20 <20 3+ 











Water and methanol are highly recommended for this type of research (Akihisa et al, 
2005; Jimenez-Arellanes et al, 2003; Rai and Acharya, 1999). Other research has been 
carried out using non-polar solvents a choice necessitated by structural feature of MTB 
mycolic cell wall (Gomez-Flores et al, 2008). However, in other areas of research low 
polar solvents such as hexane and acetone based extracts have proved quite effective 
MTB inhibitors (Torrado-Truiti et al, 2003; Jimenez-Arellanes et al, 2003; Molina 
Salinas et al, 2006) these findings seems to concur. 
 
An argument was raised related to 1% percent proportion method’s application especially 
when one has to differentiate between growing 1% of a strain on a certain drug 
concentration versus an MIC test whereby a small quantity of inoculum is used. Apart 
from pyrazinamide which is an exception, there is no evidence suggesting that using 
smallest inoculum concentration would enhance the ability to differentiate between 
sensitive and resistant strain (Zhang et al, 2003). It was recommended that if one wants to 
establish the proportion of susceptible and resistant organisms in a heterogenous mixture, 
one should therefore setup a decreasing order of drug concentrations to be incorporated 
onto an agar as opposed to calculating inaccurate from dilutions on negative controls or 
drug-free medium (Matchison, 2005). We experienced similar argument hence we took to 
the suggestion and validated the 1% proportion results with an agar dilution method and 
results in table 7.1 show concurrency. 
 
Because of the concurrency shown, an acetone-based extract therefore had to be used to 







which makes it disadvantageous to use however the results obtained are easy to interpret 
and are quite repeatable. 
 
The Rifampicin used as a positive control gave results that matched those of an acetone 
extract of IHL proving that our extraction technique worked efficiently, they both 
displayed no growth. The aqueous extract results are disconcerting though for a 
traditional medicine that is supposed to benefit Tuberculosis patients particularly given 
that the results are based from 30mg/mL concentration which is supposedly high. It is 
generally known that to culture MTB it takes more than 3 weeks, treating TB takes even 
longer. In HIV positive patient’s reemergence of TB as an opportunistic disease is most 
likely to happen. Treatment default by patients is one of the leading courses to MDR-TB 
and XDR-TB development (Morozova et al, 2003). The fact that an aqueous extract did 
not display growth inhibition meanwhile an acetone extract did, still makes traditional 
medicine an important intervention not only for its therapeutic benefits, but also as a 
strong lead for new drug discovery (Dimayuga and Garcia, 1991).  
In a study done by Eloff (1998a) in which several solvents were examined for their 
extraction potential by way of a) solubilizing antimicrobials from plants, b) rate of 
extraction, c) ease of removal and d) toxicity in bioassays, acetone was overall ranked 
high on that solvent list. 
 
In another study by Lall and Meyer (2000) that seek to establish antibacterial activity of 







extract best yield compounds that are active against gram positive bacteria at 5.0 mg/mL 
concentration. 
 
The traditional medicine activity may sometimes appear inactive in vitro however 
become active when applied in vivo such as prodrugs. Prodrugs are initially metabolized 
prior to becoming active in vivo (Tangyuenyongwatana et al, 2009). Thus there is a 
possibility that an aqueous extract of IHL may have acted like prodrugs. 
 
High medicinal concentrations may be required to bring about activity. An extract 
isolated of T.  riparia showed antimycobacterium activity at 100 mg/mL (van Puyvelde et 
al, 1994).    
 
7.6 Conclusion 
IHL has displayed antimycobacterial activity an activity only realized with acetone-based 
extract as opposed to what should readily be displayed by an aqueous extract. The results 
acquired with an agar dilution method compare to those obtained with 1% proportion 
method. The acetone-based results of IHL give an indication that it may possibly give an 
active lead with antimycobacterial properties and possibly a novel compound for 
treatment of MDR/XDR-TB. Nevertheless, further investigations are warranted to isolate 
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Introduction: Plants products are rapidly gaining recognition as possible anti-HIV 
agents (van Wyk and Gericke, 2000; Scott et al, 2004). Clinical cases of patients 
displaying signs of improvement after taking traditional medicines are amongst some of 
reasons that generated interest into their properties.  
Objective: We conducted an in vitro investigation into the anti-HIV properties of 
Ihlamvu laseAfrika (IHL) that is currently used by people living with AIDS (PLWA) for 
managing viral replication, in vivo.  
Materials and Methods: A “neat” aqueous extract of IHL was diluted 5 folds until -8
th
. 
An XTT technique was used to assess cell viability of viral infected MT-4 cells cultures 
after exposing to several concentration of IHL, azidovidine (AZT) served as a positive 
control.  
Results: Results showed that at high doses, the IHL increased proliferation of uninfected 
and infected cells, cell protection reached maximum. At approximately -3.29 dilution, 
IHL proved to be toxic to both uninfected and infected cells, below -3.29, most cells 
became non-viable. 
Conclusion: IHL did not demonstrate an antiviral effect at these concentrations. 








Plants products are rapidly gaining recognition as possible anti-HIV agents (van Wyk and 
Gericke, 2000; Scott et al, 2004). Clinical cases of patients displaying signs of 
improvement after taking traditional medicines are amongst some of reasons that 
generated interest into their medicinal properties. Resolution of HIV/AIDS symptoms 
may include improvement in appetite, exercise tolerance, mood, sense of well-being, and 
weight gain and upregulated CD
4
 T-cell count after taking traditional medicine for six 
weeks (Gericke et al, 2001). Moreover, there are also serious claims made by some 
traditional health practitioners (THPs) that they cure HIV. Hence in order to validate 
these claims and regulate the informal and booming traditional medicine industry, 
research into these products is therefore necessitated. Subsequently traditional medicines 
that often get selected for scientific research are based on anecdotal use by AIDS patients 
hence it had to show relative anti-HIV activity in vivo (Farnsworth, 1994; Fabricant and 
Farnsworth, 2001). Most often in vitro research is usually superseded by the in vivo 
application of medicines within public domain, therefore no scientific proof or conclusion 
could be made regarding the efficacies of these medicines making for what could be 
termed reverse pharmacology.  
 
Some plants have proven useful against infectious organism e.g. tuberculosis (TB) which 
indicate that they may have antibacterial, or immunomodulatory properties (van Wyk et 
al, 2000; Bouic, 1996; Yang et al, 2004; Malini and Vanithakumari, 1990). Hypoxis 
hemerocallidea is a typical example of plant species that has proved beneficial to HIV 






activity is attributed to its macerated rhizome that was used for wound healing and 
multiple AIDS related opportunistic infections (Bouic, 1996; Ojewole, 2002). 
 
In another study done by Klos et al (2009) on South African medicinal plants, the ethanol 
extract of Leonotis leonurus significantly inhibited HIV-1 by 33% while both aqueous 
and ethanol extracts of Bulbine alooides displayed greater than 50% inhibition. Some 
traditional medicinal products have displayed activity at different points of drug 
intervention in HIV‟s life cycle (Masutse et al, 1999). A methanolic extract of the root of 
Bridelia micrantha (Hochst) Baill (Euphorbiaceae), an RNA-dependant-DNA (RDDP) 
also displayed activity of HIV-1 RT with an IC50 of 7.3µg/mL (Bessong et al, 2006).  
 
The possibility of inhibiting reverse transcription catalytic activity can result in failure of 
the virus to transcribe its genetic information that regulates translation of viral protein 
into provirus formation. This is a key step since the viral DNA is copied into cell‟s DNA 
hence, the cellular machinery manufacture new viral DNA as programmed in the form of 
RNA. T-cell could only get infected once viral RNA has been transcribed into DNA and 
that is enabled by reverse transcriptase enzymes (AIDSMED, 2001). Nucleoside 
analogues are that class of drugs responsible for inhibiting HIV active replication. 
However, challenges often faced with highly active antiretrovirals therapy (HAART) 
regimen include toxicity, development of resistance, limited availability, requires strict 
adherence to therapy, high cost and serious lack of curative effect (Friedland, 1997; 
Romanelli, 2005). South Africa is incredibly rich in biodiversity and hence medicinal 






It is plants‟ lowcost that enable possible production of biomedicine and vaccines 
(Karasev et al, 2005). These activities could be based on phenylcoumarins and plant 
proteins that displayed best anti-HIV activity with regards to NF-αB and Tat protein 
inhibition (Akesson et al, 2003; Reddy et al, 2004; Marquez et al, 2005).  
 
IHL is hypothesized to act as a non-specific inhibitor of opportunistic pathogens in 
persons infected with HIV/AIDS. In the previous chapters, IHL was screened for anti-
MTB, anti-fungal and anti-HSV activities and for this section it would be screened for its 
anti-HIV property. 
 
8.2 Materials and methods 
8.2.1 Reagents and Chemicals 
8.2.2 Chemicals 
Colourless RPMI-1640 
In vitro toxicological assay kit XTT based (Sigma-Aldrich, Missouri, USA) 
Phosphate buffer saline (PBS) 
 
8.2.3 Viruses 
MT4 cell line used was obtained from the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH. HIV Viral load assay was performed with the 






Virus isolate HTLVIIIB was used (AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH). The XTT Assay was performed with the In vitro 
toxicology kit, XTT Based (Sigma), Lot #. 126K8418. 
 
8.2.4 Cytotoxicity Testing 
Viral propagation was carried out on MT-4 cells. Cells were maintained on phenol red 
RPMI 1640 supplemented with 10% heat inactivated fetal calf serum, 1% L-glutamine 
and antibiotics. A 96 well flat bottom plate (Costar, Cambridge, MA) was used for 
susceptibility testing. In preparation for susceptibility, cells were spun at 1000rpm and at 
RT for 5min, supernatant discarded and the colourless RPMI was added. Fifty microliters 
of MT-4 cells at 6X10
5
 cells/mL concentration was added into each well. Furthermore, 
50µL of colourless RPMI was also added onto row B-D, columns 2-10 (depending on 
number of dilutions). It is important to note that these rows contained mock infected 
(uninfected) cultures. Virus was thawed, diluted (100-300 TCID50) and added on the rows 
E-G, columns 2-10 (depending on the number of dilutions). These rows contained virus 





) and a blank. In order to assess possibility of cytotoxicity, the virus-free 
control wells contained dilutions well mentioned above for medicinal extract. Drug 
susceptibility plate was incubated at 37
°
C in a humidified 5% CO2. After 5 days plates 
were read in spectrophotometer (Molecular Devices, Menlo Park, CA). Fifty microliters 
of XTT was added to each well and plate was gently agitated in a rotator for an even 






spectrophotometer at 450nm wavelength and reference wavelength of 650nm. Results 
were tabulated on excel template and both IC50, EC50 and selectivity index calculated.   
Wells were taken as positive for HIV if the optical density was less than OD of the 
control wells. Effect of medicinal dilutions on cell viability was assessed. Its effect was 
expressed as the amount of traditional medicine required to prevent a reduction OD 
compared to mock infected cultures. The concentration of IHL required to prevent 50% 
reduction OD was defined as IC50. 
 
8.3 Results   
The results displayed in figure 8.1 and 8.2 given below were acquired through an 
antiviral screening protocol that was derived from cytotoxicity assay with tetrazolium 
salt, the XTT.  
 
 
Figure 8.1: HIV susceptibility results with Azidothymidine (AZT) applied to both 






(Dilutions expressed in log5 i.e. 5-fold dilutions. B represents the „Blank‟ or a negative 
control i.e. the culture medium (RPMI) without tests substance. 0 represents „neat‟ 
substance. -1 to -8 represents the successive 5-fold dilutions on a logarithmic scale i.e. 
1/5, 1/25, 1/125, 1/625, 1/3125, 1/15625, 1/78125) 
 
The positive control, AZT (figure 8.1) tested demonstrated the expected antiviral activity 
towards uninfected cell, high cell viability at low dilutions and less cell viability at high 
dilutions. The reported selectivity index approximates the published selectivity index of 
1027. As AZT become diluted cell protection is enhanced and so is cell viability. 












According to results displayed in figure 8.2, it can be noticed that at high doses of IHL 
there is an increased number of uninfected and infected cells. At approximately -3.29 
concentrations (based on fig 8.2 above it is represented by -3) it has proven to be toxic to 
both uninfected and infected cells. Below a -3 concentration, most cells were killed. As 
per explanation given previously, what became apparent is that lower doses did not kill 
uninfected cells but killed infected cells only. Hence, the test substance therefore 
demonstrates greater or equal to 50% protective effect. 
 
8.4 Discussion 
In the previous chapters tests conducted to establish antimicrobial susceptibility towards 
IHL as well as MIC, the IHL was initially lyophilized, weighed and reconstituted and 
extracted with several solvents of varying polarities. That may or may not present a great 
possibility that IHL could either be overly concentrated or diluted, hence give a 
misguided impression on IHL‟s efficacy. Hence in the test for anti-HIV properties, the 
IHL was presented as a “neat substance” thus in its original formulation as presented to 
us by our THP, suffice to say that it was destined for public consumption despite 
laboratory tests and clinical trials being conducted. Nevertheless, it had been 
hypothesized that IHL is a non-specific repressor of opportunistic infections in people 
living with HIV and AIDS related infections. Traditional medicines are known to have a 
positive effect on AIDS patients. They could either exert their activity by suppressing 







The antitumour XTT protocol as designed by Weislow et al (1989) ensured preliminary 
evaluation of cells growth characteristics in microtiter trays, and drug dilutions. Firstly, it 
was made certain that there would be sufficient time during the test, for the virus to target 
cells or modulate cell growth.  Secondly, it had to be ensured that time was sufficient for 
antiviral activity of the test substance and finally, it had to be determined that cell culture 
growth and hence XTT formazan production would not exceed the limit set for its 
measurement with the spectrophotometer used. 
 
The XTT protocol makes use of chronically infected H9 cells as a virus source. In theory 
mock-infected cells (uninfected controls) would normally give out a soluble orange XTT 
formazan colour and therefore yield high optical densities (Weislow et al, 1989) and 
these are drug protected cells. On the contrary, those cells not protected by drugs are 
killed by virus hence not allowed to proliferate thus presents a low optical density. The 
50% cytotoxicity concentration (CC50) is defined as that concentration of the test 
substance that reduces the absorbance of uninfected control by 50%. Meanwhile, the 
effective concentration at 50% (EC50) is defined as that concentration of test substance 
that achieves 50% protection in infected cultures (Weislow et al, 1989).  
 
It has been established that AZT is toxic at higher concentrations (Mir & Costello, 1988; 
Duesberg, 1992; Freiman et al., 1993; Tokars et al., 1993; Bacellar et al., 1994; Goodert 
et al., 1994; Seligmann et al., 1994) which subsequently explained cell viability that was 







XTT is a thus a relatively simple and reliable assay used for measuring of in vitro 
antiviral activity and cytotoxicty. Hence the technique determines both infection and 
subsequent viral replication in target cells that is correlated to formazan produced 
(Weislow et al, 1989). Although the technique may have proved useful it is however not 
without limitations. False positive results have been said to be due to the following: a) 
non-specific reduction of XTT by tests compound, b) poorly understood drug-cell-XTT 
interaction and c) human error. 
 
8.5 Conclusion 
IHL did not demonstrate an antiviral effect at the concentrations tested. However, what 
become apparent with these tests is the toxic effect the substance seems to have (IC50=-
3.29). This warrants further studies that are necessary to give explanation to the apparent 
increase in percentage mockinfected and infected cells between dilutions -2 and -1. The 
EC50 cannot be calculated since the 1% protection is always below 50%.  
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9.1 Overall Discussion and Conclusion 
 
The incessant challenge of antimicrobial drug resistance presents a serious challenge to 
current drug regiment hence the continuous search for novel entities from medicinal plant 
is important (Kuete et al, 2010). Medicinal products play a crucial role in drug discovery 
and new products development (Newman et al, 2007). Some regard plants as a significant 
source of highly active antimicrobial metabolites (Gibbons, 2005, Pauli et al, 2005).  The 
continuous scientific search for antimicrobial entities from traditional medicine, led us to 
investigate the antifungal, antiviral and the antimycobacterial properties of IHL. IHL is 
botanically constituted of plants mostly found in the southern African region both coastal 
and inland, according to our THP. IHL is currently used by immunocompromised patients 
as a non-specific repressor of pathogens AIDS patients usually present with. 
 
The preliminary cytotoxicity assays (MTT) revealed IHL as not toxic to mock-infected 
cells despite prolonged exposure to the traditional medicine. This is crucial because of the 
duration it takes for some cultures to grow such as MTB is prolonged. Moreover, AIDS 
bestows lifelong sentence to treatment, cells should therefore be protected from death. In 
retrospect HeLa cell line that was exposed to IHL experienced superb cell growth 
enhancement. Cell viability that was done according to trypan blue test on HeLa cells 
displayed insignificant cell death (table 4.0) after exposing cells to several concentrations 
of IHL for 24hours. When considering damaged caused in the event of toxic medicinal 
substance ingested, cell numbers become drastically reduced. For HIV assay, chronically 
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persist despite being infected with HIV or die. Alternately the virus would be killed 
whilst cells remain viable. It was noticed however, that IHL could not demonstrate anti-
HIV effect at the concentrations tested. Instead the toxic effect of IHL particularly at 
(IC50=-3.29) was noticed. In essence, HIV conferred deleterious effect onto cells since 
acute viral infected cells had undergone apoptosis. A similar phenomenon could have 
been experienced with HSV infected cells since HSV would also confer cytopathic effect. 
 
Necrotic cell damage can be intrinsically linked to damage in genetic material due to 
mutagens found in man as well as organisms. Development of most cancers is attributed 
to these mutations including degenerative disorders and genetic defects in offsprings 
(Carino-Cortes et al, 2007). South African plants have been subjected to mutagenic 
studies (Elgorashi et al, 2003, Verschaeve et al, 2004, Reid et al, 2006, Verschaeve et al, 
2008). Plant poisoning on the other hand, has not been well recorded due to serious lack 
of report by the consumers (Steenkamp et al, 2006).  
 
IHL has indeed proved to have positive effects on HIV/AIDS. However, we had to 
establish whether such effects could either be directly due to inhibition of HIV causing 
AIDS or indirectly due to its inhibition of organisms causing secondary opportunistic 
diseases. 
 
Previously it was mentioned that HIV susceptibility assay was carried out on „neat‟ 
concentration of IHl, in order to preempt and compare the would-be in vivo clinical trials 
results to in vitro results.  The working concentration of the „neat‟ substance remained 
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working concentrations relative to the amount of medicinal product we could freeze-dry 
and lyophilize hence we could not possibly achieve the original concentration since small 
aliquots were used. Our aim was to standardize the traditional medicine in order to 
achieve certainty in our experiments. It was realized that our standardized concentrations 
were relatively weaker however they proved effective against microorganisms it was 
tested against. For example, an MIC of IHL as tested against Candida albicans and 
Cryptococcus neoformans was 1.0mg/L on solid media (with the disk diffusion method) 
but on liquid media (with broth microdilution assay) MIC‟s were 1.0 mg/mL and 2.0 
mg/mL, respectively. Furthermore, the MIC of the test substance as tested against MTB 
cultured on Middlebrook agar was 16mg/mL. The last MIC acquired with PCR technique 
obtained on HSV susceptibility assay was 1.25mg/mL. All concentrations were compared 
against the activity of the „neat‟ substance which was tested against HIV. When 
considering activities of the above MIC‟s they reveal that 16mg/mL becomes the 
effective dosage required to formulate IHL  that might circumvent cytotoxocity and 
possibly mutagenicity assuming that treatment is a lifelong process as witnessed with the 
HAART program.    
 
The solvents used to extract the bioactive compounds from IHL varied from one 
microorganism to the next. An active principle or the target compound in an extract that 
bears antimicrobial properties is highly influenced by the solvent used for its extraction 
(Ncube et al, 2006). It was established that both C. albicans and C. neoformans were 
strongly inhibited with an aqueous extract of IHL. Hence it is safe to deduce that water 
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study done by Steenkamp et al. (2007) it was revealed that a crude methanol and water 
extracts of Combretum molle (root), Piper capense (bark), Solanum aculeastrum (fruit), 
Syzygium cordatum (bark) and Zanthoxylum davyi (bark) and aqueous bark of Afzelia 
quanzensis and root extract of Tabernaemontana elegans contained antifungal 
compounds that inhibited growth of C. albicans at < 1mg/mL. Furthermore, bioassays 
resulted in the identification of active principles with antifungal properties from these 
extracts for example, tannins and saponins were isolated from Terminalia species (Baba-
Mousa et al, 1999), tannins were also isolated from Combretum species (Kolodziej et al, 
1999) and ecodysteroids was isolated from Asparagus species (Dinan et al, 2001). 
 
In our study the main constituents of the aqueous extracts identified with an UPLC-MS 
comprised 16 compounds that were identified as steroid, alkaloids, phenols, 
binaphthoquinone, homoisoflavonoids, terpenoids, triterpenoids, coumarins and saponins. 
This study was however limited to antimicrobial properties of IHL, but there exist 
secondary metabolites with other properties such as immunomodulation, antioxidants, 
analgesics etc found within this tonic. 
 
Schmourlo and co-workers (2005) conducted a study in which antifungal agents 
precipitated with ethanol according to bioautographic method, resulted in an aqueous 
extract of Mormodica charantia totally losing its antifungal activity against Candida 
albicans and Cryptococcus neoformans after fractionation. Lost of activity was attributed 
to some proteins that possessed hyperglycaemic, antitumour, antileukemic and antiviral 
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(Yeung et al, 1988; Hara et al, 1989; Arazi et al, 2002; Parkash et al, 2002) found in M. 
charantia that may have been lost during precipitation. It was therefore deduced that 
antifungal activity may have been attributed to the aforementioned proteins. Such an 
observation also explains the reduction in antifungal activity of an aqueous extract of IHL 
which was upon its extraction with several organic solvents of differing polarities 
compromised activity. The water-soluble compounds for example fabatin, 
polysaccharides, proteins and some lectins have displayed favourable inhibitory activity 
on viruses that would adsorb to their host (Zhang and Lewis, 1997). This also concurs 
with 70% methanol extract which practically dissolved a lyophilsed product of IHL when 
less polar solvents couldn‟t. Herpes simplex virus II was strongly inhibited by methanol 
extract of our traditional medicine (figure 5.2) than other solvents‟ extracts which 
coincide with the above findings.       
 
 
The test for antimycobacterial properties of IHL yielded peculiar findings especially since 
an aqueous extract did not show activity. The aqueous extract represent „neat‟ sample that 
is available to the public. However, upon its extraction with solvents of differing 
polarities, some activity was noted in which an acetone extract gave the best MTB growth 
inhibition than the rest (Figure 7.1). It can be then be concluded that acetone best extract 
naphthoquinones as it was the case with diosindigo A, an active principle isolated from 
Euclea natalensis (van der Vijver, 1974).This was further confirmed in study conducted 
by Lall and Meyer. (2000), that water and acetone showed relatively best 
antimycobacterial results when used to extract an active principle in Euclea natalensis. 
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EtOH justifies activity of the ethanol extract of IHL, but acetone extract remained 
unsurpassed.  
 
Research has established that anti-HSV properties of IHL are attributed to verbascoside. 
In previous studies done by Martins et al (2009), verbascoside extracted with ethanol 
displayed the best anti-HSV-1 and 2 growth inhibition results which concur with our 
findings. In our anti-HSV assay, we observed an insignificant variation (p = 0.2473) 
between methanol and ethanol extracts of IHL (figure 5.2).   
 
Amides such as methylillukumbin A that were isolated from Mauritine species displayed 
antifungal activity. Moreover, compounds such as thalebanin B (Greger et al, 1996), 
kuguacin J (Kimura et al, 2005) and quecertin (Roy et al, 1996) also possess antifungal 
activity, despite several solvents used for extraction. The presence of the aforementioned 
compound presented a significant fungal growth inhibition when compared to viral and 
mycobacterial organisms with regards to MICs.  
 
 
It has been established that during chemical profiling of IHL that it would provide with 
specific secondary metabolites responsible for antimicrobial activities plus further useful 
properties not intended for this study such are immunostimulation, anti-inflammatory, 
analgesics and antioxidants. The established secondary metabolites this tonic presents 
ranged from amides, flavanoids, terpenoids, triterpenoids, sterols, quinones, alkaloids and 
naphthoquinones (table 3.0). The compounds that do not possess antimicrobial properties 
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antioxidants properties. Some compounds were unintentionally unidentified as it can be 
seen from the chromatogram.  
 
Table 9.0: Summary of isolated principles with their respective antimicrobial properties 
 
Secondary Metabolite Compound Biological function Reference: 
phenethyl/styrylamine-
derived amides 
Thalebanin B Antifungal Greger et al, 1996 
Naphthoquinone 2-methyl-3-(piperidin-1-yl).. Anti-MTB Mital et al, 2010 
Cucurbitacins Kuguacin B Anti-HIV Chen et al, 2008 
Cucurbitane-type 
triterpenoid 
Kaguacin R Antiviral Chen et al, 2009 
Amides Methylillukumbin A Antifungal Greger et al, 1996 
Homoisoflavonoids 3,5-Dihydroxy-4,7-
dimethoxyhomoisoflavonone 
Antimicrobial Jiang et al, 2007 
Quinone Anhydrocochlioquinone A     Antitumour Jung et al, 2003 
Cucurbitane-type 
triterpenoid 
Kuguacin J Antibacterial, 
antifungal 
Kimura et al, 2005 
Phenolic antioxidant Verbascoside Anti-HSV Martins et al, 2009 
Flavonoid Quecertin Antifungal Roy et al, 1996 
Triterpenoids Isoferuloyllpeol Anti-MTB Weigenand et al, 
2004 
Cyclopeptides alkaloids Mauritine H Antifungal, 
antibacterial 
Pandey et al, 1990; 
Tschesche et al, 1977 
Flavonoid Kaempferol Anti-oxidant, 
immunostimulant 
Shrivastava and Patel, 
2007 
Alkaloid Nuciferine Anti-HIV, 
antimicrobial 
Cho et al, 2003, 
Kashiwada et al, 
2005 
Amaryllidaceae alkaloid Narcissidine Antiviral Furusawa et al, 1970 




It has been scientifically validated and proven that the pharmacological properties present 
in IHL warranted its use against HIV/AIDS and its secondary opportunistic diseases. 
However, the results do not agree with the hypothesis initially presented. It was 




Overall Discussion and Conclusion 
206 
AIDS or via inhibiting microorganisms causing opportunistic diseases. According to 
results, it was established that IHL is capable of inhibiting growth of microorganism 
causing opportunistic infections. This overrides the presence of secondary metabolites 
such as kuguacin B and nuciferin with anti-HIV activities established. Such inability to 
initiate anti-HIV activity might probably be dose-dependent since in literature their anti-
HIV activities were established.  
 
The study further revealed the important role played by THP not only to their respective 
community but the scientific community at large regarding their contributions. 
Traditional medicine is undoubtedly infested with some charlatans who exploit the poor 
in a bid to get rich creating “AIDS opportunism” (Richter, 2003). These findings further 
add to the call already made to respective governments to streamline traditional health 
practices into the mainstream. The efficacy displayed by IHL offers a steppingstone 
towards the construction and development of pharmacopeia of TM‟s and monographs. 
Published clinical results of traditional medicines are currently minimal in South Africa 
despite strides being taken to validate most TMs currently marketed. Such information 
would assist in the development of sound policies that can pave a way for the regulation 
of production, quality testing, safety standards, efficacy as well as preservation of natural 
resources. The need for quality and safety assessment ranks high in Africa and Latin 
America that have approximately 80% depending on traditional medicines (WHO Fact 
Sheet No. 134, 2008). The research output that has been offered by world renowned 
scientist such as van Staden, Afolayan, Lall, Dilika, Meyer, Eloff and others on South 
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that can eventually afford status enjoyed by western medicine. However, the aim is not 
competition but to increase affordable healthcare and social benefits to respective 
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Chemical Preparations:  
 
Trypsin : 
- 25g trypsin dissolved in 1litre distilled water (2.5% solution) 
- Filter sterilize using 0.1um filter 
- 20ml of 2.5% soln made up to 200ml with PBS (0.25% solution) 
- Aliquoted  1ml into each vial and stored at -20◦C 
 
EDTA: 0.5M 
- Weigh 2g NaOH pellets, add 80ml water 
- Place on magnetic stirrer, dissolve 
- Add 18.6g  of EDTA to dissolved NaOH soln 
- Soln must look clear 
- pH soln to pH 8. this will help clear up the soln 
- Once dissolved, make up to 100ml. 
- Autoclave. Dilute 1:5 with PBS/ autoclaved water 
- Alternatively make up initial soln to 500ml and autoclave 
- Aliquote 1ml into each vial and store at -20◦C 
 
Trypan Blue: 







- Add 20ml foetal calf serum, 60ml of media used for cell line and 20ml of DMSO  
in the above order 
- Filter through a 0.22um filter and store in 20ml at -20◦ C 
-  
McFarland Standard 
- A 0.5 McFarland standard is prepared by mixing 0.05 mL of 1.175% barium 
chloride dihydrate (BaCl2•2H2O), with 9.95 mL of 1% sulfuric acid (H2SO4). 
Store in dark or cover glass bottle with aluminiumfoil. 
Preparation of 10% FCS 
- Aliquote 500µL of FCS into 4.5mL culture medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
